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Synthetic materials for use in blood contacting applications have been studied for many 
years with limited success.  One of the main areas of need for these materials is the 
design of synthetic vascular grafts for use in the hundreds of thousands of patients who 
have coronary artery bypass grafting, many without suitable veins for autologous grafts.  
The design of these grafts is constrained by two common modes of failure, the formation 
of intimal hyperplasia (IH) and thrombosis.  IH formation has been previously linked to a 
mismatching of the mechanical properties of the graft and has been overcome by creating 
grafts using materials whose compliance mimics that of the native artery.  Several 
techniques and surface modification have been designed to limit thrombosis on the 
surface of synthetic materials.  One which has shown the greatest promise is the 
immobilization of Thrombomodulin (TM), a protein found on the endothelial cell 
membrane lining native blood vessels involved in the activation of the anticoagulant 
Protein C (PC).  While TM immobilization has been shown to arrest thrombin formation 
and limit fibrous formations in in-vitro and in-vivo experiments, it has shown to be 
transport limiting under arterial flow.  On the endothelial cell surface, TM is co-localized 
with Endothelial Protein C Receptor (EPCR), which increases PC transport onto the cell 
surface and increases PC activation via TM between 20-100 fold.  This dissertation will 
 
 
describe the chemical modification of medical grade polyurethane (PU), whose 
compliance has been shown to match that of native arteries.  This modification will 
enable the immobilization of two proteins on an enzymatically relevant scale estimated at 
less than 10 nm.  This dissertation will further describe the immobilization of the proteins 
TM and EPCR, and analyze the ability of a surface co-immobilized with these proteins to 
activate the anticoagulant PC.  Finally, it will compare the ability of this co-immobilized 
surface to delay fibrous clot formation when compared to unmodified PU, albumin or 
heparin coated surfaces.   
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Introduction to Synthesis of an Endothelial Cell Mimicking Surface 
Containing Thrombomodulin and Endothelial Protein C Receptor 
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The design of biomimetic implants has lead to the development of materials who 
mechanical properties, 3D structure, adsorption or catalytic activity mimic those of the 
native tissue.  The need for these types of materials is especially evident in the design of 
materials for vascular applications where mechanical property mismatch can lead to 
neointimal hyperplasia formation[1] and nonspecific protein adsorption[2, 3] and a 
failure to mimic the catalytic processes of the endothelial lining[4-6] can lead to 
thrombosis, occlusion and failure. 
 
Chronoflex AR™, a medical grade polyurethane (PU), has been molded into grafts which 
have been previously shown to mimic efficiently the compliance of the native vessel seen 
in arterial flow.[7]  However the use of these grafts has been limited by activation of the 
proteolytic clotting cascade that PU as well as other synthetic polymers exhibit which 
ultimately leads to the formation of emboli, occlusions and failure.[2]  Several surface 
modification techniques have been designed to passivate the material surface through the 
immobilization of proteins or small biomolecules or polymers designed to reduce the 
hydrophobicity of the surface.[5]  Others have attempted to create surface modifications 
which interact with the natural regulatory mechanisms of the body to prevent thrombin 
formation and occlusion.  These modifications include direct thrombin inhibitors 
designed to mimic the affect of the enzyme hirudin found in snake venom[8] and 
immobilization of heparin[4, 9] or thrombomodulin (TM)[4, 10] found on the endothelial 
cell surface.   
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Thrombomodulin (TM) is a transmembrane glycoprotein found on all vascular 
endothelial cells.[11]  In vivo, TM binds thrombin in a 1:1 ratio and acts as a cofactor for 
the activation of the anticoagulant Protein C (PC).[12]  Once activated, PC reacts through 
competitive inhibition with Factor Va and Factor VIIIa.  The inhibition of these 
molecules inactivates the Factor VIIIa / Factor IXa complex used to produce Factor Xa 
and the Factor Xa / Factor Va complex used to activate thrombin, the central molecule in 
thrombus formation. 
  
TM has been coated or immobilized onto a variety of biomaterial surfaces including 
PEG-modified glass, polyethylene (PE), poly-tetrafluroethylene (PTFE) and polyether-
urethane (PEUU) and the bioactivity of immobilized TM was verified by biochemical 
assays. [10, 13-15]  More recently, arterial grafts produced from transplanted veins have 
been studied and it has been shown that when the concentration of TM is increased from 
venous levels to that found in arteries, thrombin formation is completely arrested.[16]  In 
another study, TM immobilized polyester vascular grafts were able to completely prevent 
hyperplasia formation which is normally associated with fibrous clot formation in 
vivo.[17]  These results suggest that a TM immobilized surface could have the potential 
for completely preventing the thrombosis on the material surface which currently 
prevents the construction of artificial small diameter vascular grafts.  However, surface 
coatings of TM do have limits as it has been shown that under flow conditions PC 
activation by TM becomes transport limited.[18] 
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The native regulatory mechanisms found on the endothelial lining can be extremely 
complex and often require multiple signals found on the cell lining.  One such 
mechanism is the TM activation of the PC.  In this mechanism, PC is bound to 
endothelial protein C receptor (EPCR) and presented to TM for activation.  In the 
absence of EPCR, this reaction has been shown to be up to 86% less efficient.[19, 20]  
However, because the two proteins interact on the same PC molecule, EPCR and TM 
must be co-localized in a small area, based upon the size of the proteins, at a distance <10 
nm.[21] 
 
The requirement that the two proteins be immobilized on the 10 nanometer scale requires 
a degree of patterning which has been produced through different methods of 
lithography, however these methods have been developed for use on silica chips, which 
has not been yet been adapted for use on organic polymers.[22, 23]  Because the ceramics 
do not have the necessary modulus and compliance for use in vascular systems, and the 
lithography methods which can be resolved to the 10 nm scale have not been adapted to 
use on polymer surfaces[24-26], a new method for ordered immobilization must be 
developed. 
 
In chapter 1 of this dissertation, a chemical modification will be described to create a bi-
dentate functional group capable of immobilizing two proteins on the necessary sub 10 
nm scale.  This chapter will discuss the synthesis and characterization of the modification 
done across the solid-liquid interface of a prefabricated sample of Chronoflex AR™ PU.  
In this chapter, the cellular and blood biocompatibility of modified polymer samples will 
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be compared to unmodified controls to ensure that these properties remain unchanged.  
Because of the importance of mechanical properties in the use of PU for vascular grafts, 
chapter 2 examines the mechanical properties of modified PU and compares modified 
and control samples in energy loss fatigue experiments.  Chapter 3 gives a description of 
thrombosis and device initiated thrombosis.  The chapter describes the TM / EPCR / PC 
anticoagulant mechanism and explains the production and purification of recombinant 
EPCR.  This chapter also examines random immobilizations of TM and EPCR on a 
membrane surface analyzes.  In chapter 4, we finally examine the effects of sequential 
co-immobilization of TM and EPCR on the ability of TM to activate PC.  Also in chapter 
4 we examine whether TM / EPCR immobilized surfaces are able to delay fibrous clot 
formation as examined by thromboelastogaph.  The final chapter discusses future 
directions for this research including the TM / EPCR surface and other possibilities for 
bi-dentate functional group. 
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Chapter 1 
Controlled Co-immobilization of Proteins on Polyurethane. 
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Abstract 
 
 Surface modification of implantable materials have been studied as a manner to 
passivate the material and create a more biocompatible implant.  However in recent 
years, the systems used for surface modification have moved to systems which mimic 
that found on the cell surface.  As a result of these more complex systems, methods have 
been developed to pattern the immobilization of biomolecules to create surfaces capable 
of the complex events which take place on the surface.  These surfaces are limited by the 
need of a metal or silicon chip, which do no closely match the mechanical properties of 
soft tissue of methods which are not tuneable to the enzymatic scale for methods using 
polymers.  This paper describes a method for sequential patterning of two proteins or 
biomolecules onto a polyurethane support who mechanical properties closely resemble 
those of vascular tissue.  This method creates a bidentate functional group capable of 
controlled immobilization of two different molecules, each of whose concentration is 
similar to those currently reported by immobilization on polyurethane through other 
methods.
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Introduction 
 Implanted medical devices are of increasing importance in the practice of 
medicine and it is estimated that more than 3-million people in the United States have 
long-term implants like vascular grafts, pacemakers, catheters and joint replacements.  Of 
particular interest is the design of small diameter vascular grafts as patients in need of 
arterial grafts for bypass operations do not have suitable autologous vessels.[27]  Several 
types of materials have been tested in experimental configurations including initial 
studies where tubing composed metal or glass were used.[28]  Today, the importance of 
matching the mechanical properties of the graft to those of the artery and its relationship 
to long term survival is known.  Because of the elasticity and compliance of native 
arteries, development of artificial grafts has moved to polymers and recovered biological 
materials.[29] 
 Several different polymers have been used to generate vascular grafts.  Dacron, a 
polyester (PE) and polytetrafluoroethylene (PTFE) have both been used in the design of 
large diameter vascular grafts.  PE and PFTE grafts are porous and when exposed to 
continuous blood flow, surface induced thrombosis leads to the formation of clots around 
the pores, leading to the clogging of the pores and rendering a fibrin coated surface that 
allows the susbsequent  tissue ingrowth and partial endothelialization of the graft.  The 
thrombogenicity which allows for the tissue ingrowth, and the mechanical properties, 
both parent polymers which have a significantly different stiffness and compliance as 
compared to a natural vessel, can lead to occlusion and intimal hyperplasia at the 
interface of the graft and the blood vessel in smaller diameter vascular grafts.[29]  Efforts 
to design smaller diameter vascular graft through the use of bioresorbable polymers such 
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as polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL) and 
copolymers of these materials have been attempted.  Initial studies showed difficulty in 
controlling the degradation rate, with constructs failing due to degradation prior to the 
formation of functional tissue.  Copolymers have been employed in an effort to tailor 
both the mechanical properties and the degradation rate of polymer construct.  The most 
successful biodegradable graft is polyglycolic-co-lactic acid (PGLA) / polydioxanone 
copolymerized graft which allowed for degradation over a period of 6 months and 
resulted in 100% patency over a 1 year experiment.[30]  While this result shows promise, 
it is not yet viable for long term implantation.  Another class of materials currently being 
studied for use in vascular grafts is biorecovered materials such as collagen, fibrin and 
decellularized extracellular matrix (dECM).  Collagen composes a large concentration of 
native arteries, however the methods used to collect and process recovered collagen often 
leads to destruction of the tri-helix structure which gives collagen its natural strength and 
as a result collagen grafts have shown to possess poor mechanical strength.  Fibrin 
scaffolds are not subject to the difficulties of recovery as they are polymerized in vitro 
and are of interest since fibrin clots are the natural scaffolds for vascular regeneration.  
To date fibrin constructs combined with tissue engineering techniques have shown better 
mechanical properties than collagen constructs, however they have not meet the 
mechanical strength of native vessels or been subjected to long term in vivo studies.  
dECM has been researched as a method of providing the mechanical properties necessary 
for implantation while removing the cellular components which would lead to immuno-
rejection.  While short term studies have demonstrated good cellular infiltration, 
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explanted devices have shown immunological reaction and intimal hyperplasia at the 
sites of implantation. 
 Polyurethane (PU) is an FDA approved biomaterial being studied for use in many 
cardiovascular implantable devices such as stents, vascular grafts, tissue engineered 
scaffolds[31, 32] and constructs and heart valves as its modulus and compliance closely 
approximate those of the natural blood vessel.  The polymer also is of interest as it shows 
better biocompatibility, lesser immune response, better blood tolerance and better 
hydrolytic stability, than PE or PTFE and is more stable than the biodegradable 
constructs.[33]  Briefly, PUs are actually copolymers polymerized through the reaction of 
a diol and an isocyanate.  The resulting polymer is then classified into subclasses: as a 
poly ester urethane (PEsU), poly ether urethane (PEU), poly urethane urea (PUU) or poly 
carbonate urethane (PCU) based upon the bonds incorporated into its two subunits, 
however all urethanes contain the carbamate repeated subunit formed from the diol 
isocynate reaction.  Initial focus on biomedical devices was placed on PEsU because of 
the longtime use of polyester devices, however these materials were shown to have very 
short survival rates due to a high degree of biodegradation.  PEU are the most commonly 
studied PU with several being available commercially for medical purposes.  PCU are the 
newest class of PU being developed for medical implants, after concerns over PEU in 
long term implants (>10 years) were susceptible to oxidative degradation. 
 Two modes of failure have been closely associated with devices constructed from 
PU for cardiovascular applications, thrombogenesis and calcification.  In an attempt to 
correct for these modes of failure, research has been conducted on the surface 
immobilization of different proteins and biomolecules.  When these modifications are 
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more complex than physical absorption, they have required modification of the polymer 
either in the bulk phase, modification during fabrication or modification of the surface 
post fabrication.  The most common method for modification of PU is the incorporation 
of a reactive group during the polymerization step.  This method has been used to 
incorporate both amines[34, 35] and carboxylic acid[36-38] groups which could then be 
modified using standard coupling chemistries.  While the number of the functional 
groups is controlled through concentration during polymerization, because the physical 
structure of the polymer is changed, the bulk properties of the material are also modified.   
It is also unclear in the case of amine incorporation if polymer becomes branched.[35]  
Modification of the carbamate amine (i.e. secondary nitrogen on the PU backbone) 
through the addition of a dibromo alkane extension has also been used to attach proteins 
and biomolecules.[39]   The usage of the symmetric dibromo alkane along with the 
modification in the bulk phase, has the potential to cross-link the polymer chains and 
cause a stiffening of the bulk material.  More recently, a bromo-thiol alkane has been 
used to prevent cross-linking and control the immobilization through the oxidation of a 
cysteine amino acid in the protein, though a draw back is that this linkage can easily be 
reduced in vivo.[40]  Other methods have been developed to create reactive groups on the 
surface of PU post fabrication.  The first method is a modification of the endcap of the 
polymer chain to produce an immobilization site.  Because the synthesis only modifies 
sites terminal alcohols located on the surface of a device the bulk properties remain 
intact, but the method is limited by a low concentration of reactive sites exposed on the 
material surface.  Treatment of fabricated polymer with plasma gases has been another 
effective method of functionalizing the surface.  The plasma contains radical initiators 
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which break the surface bonds of the fabricated polymers surface and creates new 
functional groups on the surface which can be controlled somewhat by the gas used in the 
plasma and the gases used to quench the radicals on the surface.  Several gases have been 
used in the plasma reaction including oxygen, ammonia, argon, methane, sulfur dioxide 
and different fluorocarbons.  In the case of methane, the fluorocarbons and sulfur dioxide, 
the researchers attempted to use a one step process to create a more inert surface.  
Oxygen, ammonia and argon have been used most frequently to for surface groups for 
further immobilization.  The functional group formed is somewhat controlled by the 
quench gas.  Air quenching produces peroxides for oxygen initiation and hydroxyl groups 
for other initiators[41], ammonia quenching creates reactive amines[42] and acid 
quenching forms carboxylic acids on the surface.[43]  While this method is advantageous 
because it can be use on a post fabricated surface, and reaction only penetrates a very thin 
surface with reactive surfaces ranging from 20 to 2000 angstroms,[44] there are 
downfalls to this method including a wide variety of functional groups are formed on the 
surface whose composition and concentration are not reproducible.  Also to overcome 
low concentrations of functional groups, researchers have found it necessary to 
immobilize polyacrylic acid extensions.[41, 43]  These extensions, which contain 
carboxylic acid groups bound to a central chain, are able to increase the number of 
functional sites, but this method does not ensure a uniform distribution of the 
immobilized molecule.  The final method used to create reactive sites on polyurethanes is 
the hydrolysis of surface polymer chains.  In this method, one to four normal sodium 
hydroxide is incubated with or without heat on a post fabricated sample allowing the base 
to cleave the chain bonds.[10]  In this method the chains which are cut are held into the 
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sample through polymer chain entanglement and reactive sites, normally carboxylic acids 
can then be modified in a manner similar to the endcap chemistry.  This method has the 
advantage of a high concentration of active sites formed, but severely weaken the sample 
should the reaction be allowed to occur over extend time.   
 To reduce the thrombogenicity of the PU, heparin, hirudin, albumin, 
thrombomodulin, different polysaccharides, chondritin sulfate and cholesterol[45] have 
been immobilized on the surface of implants.  Other studies have attempted to 
endothelialize the surface of their constructs through immobilization of RGD containing 
peptides or different growth factors.  In attempts to reduce the calcification, sulfonated 
polyethylene oxide[46, 47] and bisphosphonates[48] have been chemically immobilized 
onto the surface.  Samples containing co-immobilization of different proteins and 
biomolecules have also been prepared in an effort to better mimic the endothelial surface, 
provide growth factors and binding cites for cell attachment[42] or in an effort to control 
multiple aspects of clotting[49].  However these co-immobilizations have only been 
controlled through concentration gradients during the immobilization steps[50] or the 
sequence in which the molecules are immobilized[42, 49]. 
 Several techniques for patterning the immobilization of proteins or biomolecules 
in the design of biological sensors including photomask lithography, dip pen lithography 
/ nanografting, “direct write” lithography and nano imprinting.  In photomask 
lithography, a monolayer or polymer is coated either physically or chemically with 
photo-active polymer and a light source through a patterned cover immobilizes the target 
protein in the pattern on the surface.[51]  This method is limited by low resolution on the 
mask and has been limited to micron and submicron patterns.[26]  Recent work has 
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shown through molding methods that the distance can be reduced to 30 nm between 
wires, but more complex patterns or combining this with an immobilization step have not 
been undertaken.[25]  Dip pen lithography, also known as nanografting, is a technique 
where the cantilever tip of an atomic force microscope is coated with the protein to be 
immobilized and it is touched to a reactive surface to create the covalent bond.  The tip is 
then controlled to create the pattern on the surface.[22]  This method of lithography 
offers some of the greatest control on the size and structure of the pattern, being able to 
create lines as thin as 3 nm and separations of lines on the same order.[23]  Nanografting 
does have a considerable drawback in it is the method of patterning least able to be scaled 
up for industrial scale.  In direct write lithography, an ion beam is used to burn though a 
chemically inert surface to expose a reactive surface beneath.  In this case the 
immobilization target can be flowed over the surface for binding.[24]  This method 
contains both of the drawbacks of the two previous types of lithography as it is based on 
the resolution of the laser and its ability for reorientation during the patterning process 
but is also not able to be scaled to commercially relevant scale.  Nano imprinting is a 
method where a stamp is created through one of the other lithography and silicon etching 
processes but the proteins in question are not covalently bonded to the stamp but held 
until covalently bound to the stamped material.[52]  This process allows for overcoming 
many of the difficulties in scale up as the mold can stamp many different samples[53], 
however the resolution of the proteins patterned on the surface and the alignment of the 
stamping have been shown to be difficulties which must be overcome.[52] 
 Jang et al. developed a very interesting method for patterning a surface 
sequentially which incorporated both a nanografting step with a chemical process.  In this 
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method, a self assembled monolayer was created with two functionalities a reactive 
aldehyde and an inert diol.[54]  A protein was attached to the reactive site through 
nanografting and followed by a reduction to convert the diol into a new reactive 
aldehyde.  The new reactive sites could then be filled with the second protein.  While this 
method showed the smallest resolution for coimmobilization, it requires a nanografting 
technique which can not be scaled and that the first protein immobilized will not be 
damaged by the redox reaction to activate the diols. 
 As a result of this review, we believe that there is a need to develop patterned 
surfaces so that more complex systems of antithrombogenic surface modifications can be 
studied for potential use in vascular systems.  Because of the mechanical restrictions for 
therapeutic use, we believe that this system should be that these studies should be 
conducted on polymer implants rather than self assembled monolayers constructed on 
glass or metals which has been the source of most pattern immobilization research.  From 
the review, it is important to develop a method that is repeatable and will allow for 
scaling to a manufacturing level rather than just single micrometer sized samples. 
 This research proposes a chemical method for ordered immobilization of two 
proteins or biomolecules onto a polyurethane sample.  In this method, figure 2 and 3, a 
bidentate support will be synthesized from the surface of a post fabricated polyurethane 
sample across the solid / liquid interface.  We hypothesize that the surface can be 
modified in a manner which allows for controlled immobilization to each functional arm 
of the bidentate support, one through a nucleophilic reaction and one through a coupling 
reaction, figure 4.  We further hypothesize that by doing the reactions across the solid 
liquid interface, the bulk mechanical properties of the sample will be left intact. This 
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method will also allow for multiple samples to be modified in each batch rather than 
single sample batches which are required for most patterning methods.
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Methods 
 Sheets of chronoflex AR medical grade polyurethane were provided as a generous 
gift from Cardiotech Inc. (Cambridge, MA).   
 
2.1 Preparation of Surface Bridge 
 The chemical representation of the proposed surface modification scheme is 
shown in figure 2.  Reaction 1 will enable the addition of the first reactive oxirane moiety 
to the secondary nitrogen incorporated in the carbamate subunit of the PU backbone.  The 
addition of the reactive carboxylic acid branch of the bidentate bridge is achieved in 
reaction 2.  Reaction 3 enables the addition of a reactive oxirane functional group to 
complete the bidenate bridge.  Subsequent paragraphs will provide the experiment details 
of the surface modification. 
 
2.1.1 Reaction 1  
Solution cast polyurethane films were cut into 0.7 cm diameter samples with an average 
weight of 30 mg using a standard biopsy punch.  Under an inert atmosphere, 
approximately 1 gram of polyurethane was added to 75 mL tetrahydrofuran (THF, HPLC 
Grade 99.9%, Sigma Aldrich, St. Louis, MO) mixed with 75 mL hexanes (ACS Grade, 
Sigma Aldrich, St. Louis, MO) and the temperature of the mixture reduced to -5 oC using 
an isopropyl alcohol ice bath.  0.5 mL epibromohydrin and 0.5 mL of a 2.0 M lithium 
diisopropyl amine (LDA, Sigma Aldrich, St. Louis, MO) in THF were added to the 
mixture and the reaction was allowed to proceed for 2.5 hours with stirring.  Upon 
completion, the LDA, THF solution was removed from the PU samples and neutralized 
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with a 3% (V/V) acetic acid solution.  The PU samples were washed with 150 mL 
deionized water for 30 minutes and repeated 3 times to remove excess THF / Hexane 
solution.  Residual solvent was removed under reduced pressure, P < 0.3 Torr for at least 
6 hours. 
 
2.1.2 Reaction 2  
PU samples from reaction 1 were added to a 0.02 M 5-amino valeric acid (Sigma 
Aldrich, St. Louis, MO) in water.  The samples were allowed to react at room 
temperature for 24 hours with stirring.  Samples were washed with 150 mL deionized 
water for 30 minutes and repeated 3 times.  All absorbed water was removed by 
evaporation under reduced pressure, P < 0.3 Torr for at least 6 hours. 
 
2.1.3 Reaction 3 
Under an inert atmosphere, PU samples from reaction 2 were added to a 150 ml mixture 
THF  and hexanes (50/50 by volume) and the temperature of the mixture reduced to -5 oC 
in an isopropyl alcohol ice bath.  0.5 mL epibromohydrin and 0.5 mL of a 2.0 M lithium 
diisopropyl amine (LDA, Sigma Aldrich, St. Louis, MO) in THF were added to the 
mixture and the reaction was allowed to proceed for 2.5 hours with stirring.  Upon 
completion, the LDA, THF solution was removed from the PU samples and neutralized 
with a 3% (V/V) acetic acid solution.  The PU samples were washed with 150 mL 
deionized water for 30 minutes and repeated 3 times to remove excess THF / Hexane 
solution.  Residual solvent was removed under reduced pressure, P < 0.3 Torr for at least 
6 hours.  Samples were stored at room temperature until further use. 
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 Samples described in the above were prepared using a 50 / 50 by volume solvent 
mixture of THF and hexanes for reaction 1 and reaction 3.  However, similar reactions 
were conducted using pure THF or pure hexanes as a solvent.  Unless otherwise noted, all 
data described below has been collected from samples modified in the 50 / 50 (v) mixture 
of the two solvents. 
 
Surfaces prepared through reaction 1, reaction 2 or reaction 3 were either subjected to 
surface analyses steps or subjected to protein coupling steps.  
 
2.2 Chemical Analysis of Surface 
2.2.1 Epoxide Quantification 
Epoxide concentration was quantified as described previously.[55]  Briefly, samples were 
prepared as described above through each reaction.  Single samples were added to 12 mL 
1.3 M sodium thiosulfate (pH 7) and allowed to react at least 6 hours with shaking, at 
which time a phenol red indicator was added.  The samples were then titrated with 1 µM 
hydrochloric acid to a visual endpoint.  Samples were analyzed in duplicate from various 
batches. 
 
2.2.2 FT-Infrared Spectroscopy 
Samples were prepared from each reactive step and had all adsorbed water removed 
under reduced pressure.  Spectra were prepared from multiple samples for each reaction 
as an average of 32 scans using an IlluminatIR FT-IR microscope (Smiths Detection, 
Danbury, CT).  Sample spectra were normalized and subtracted out for comparison.  
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2.2.3 XPS Analysis 
XPS analysis was provided by the National ESCA and Surface Analysis Center for 
Biomedical Problems located at the University of Washington.  All XPS spectra were 
taken using a Kratos Axis-Ultra DLD spectrometer using a monochromatized Al Ka X-
ray and a low energy electron flood gun for charge neutralization.  X-ray spot size for 
these acquisitions was on the order of 300x700mm (Kratos 'Hybrid' mode).  Pressure in 
the analytical chamber during spectral acquisition was less than 5 x 10-9 Torr.  Pass 
energy for survey spectra (composition and detailed fluorine, nitrogen and calcium) was 
80 eV and pass energy for high resolution C1s (HRC) scans was 20eV. 
 
2.3 Mechanical Testing 
Samples were cut to size (4 mm x 32 mm bars) and reacted as described above in THF, 
Hexane or a mixture of the two solvents (50% of each by volume).  Samples were 
analyzed for stress at 37 C under a constant strain rate of 0.5 N/min to a strain of 5 N or 
failure using DMA Q800 (TA Instruments, New Castle, DE).  The data was the analyzed 
as stress as a function of strain.  The initial elastic modulus was found by calculating the 
slope of the data over the initial linear region.  
 
2.4 Material Biocompatability 
2.4.1 Leachables 
Samples prepared as described above, were added to Dubbelco’s Modified Eagles Media 
(DMEM, Invitrogen, Carlsbad, CA) cell culture media at ratio of 1:3 w/v and incubated 
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for 3 days at 37oC with mixing.  After incubation, samples were removed and discarded 
and the media, now termed as media with lechates (ML), stored at 4oC.  Fibroblast cells 
(L929, American Type Culture Collection, Manassas, VA) were seeded on a 96 well 
polystyrene tissue culture plates and cultured overnight in 100 µL fresh DMEM media 
(FM) to allow for initial attachment.  Following initial incubation, the cells were cultured 
in ML or control FM for 3 days before being released from the culture plate by the 
addition of 100 L trypsin solution (0.05% trypsin in HBSS).  The total number of cells 
was counted using a hemocytometer.  Data is presented at as a percentage normalized to 
the number of cells grown in FM. 
 
Separate samples cultured as described above were analyzed by the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) viability test.  Wells were rinsed 
with sterile phosphate buffer saline (PBS) to remove phenol red from the culture media. 
Fifty l of MTT solution (1 mg/mL in phenol red free medium) was added to each well. 
Plates were incubated for 4 hs in CO2 cell culture incubator, MTT solution was removed 
and 100 l of isopropanol was added to each well. Plates were incubated for 10 min. in 
the incubator, followed by incubation for 15 min at room temperature. Absorbance at 595 
nm was taken by a microplate reader (Elx800, Bio-Tek Instrument, Clarkston, MI, USA). 
Results were expressed in percentage of viability compared to control (% of control). 
 
2.4.2 Hemolysis 
200 µL citrated blood (Research Blood Components LLC, Brighton, MA) which had 
been diluted in a 4:5 (v/v) ratio with 0.9% saline was incubated with a 0.7 cm diameter 
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PU sample for 1 hour at 37oC with mixing.  Following incubation, the samples were 
centrifuged at 700 x g for 10 minutes and the supernatent collected.  The supernatant 
fluid was further diluted to 10 ml with the saline solution.  The resulting solution was 
read by spectrophotometer at 545 nm.  100% hemolysis was set by incubation of the 
prepared blood with 500 µL of a 0.01 N HCl solution. 
 
2.4.3 Thromboelastograph 
Platelet poor plasma (PPP) was prepared from fresh, drawn less than 36 hours prior to 
usage and never frozen, whole citrated blood (Research Blood Components LLC, 
Brighton, MA) prior to each experiment by centrifuging whole citrated blood at a force of 
2300 x g for 15 minutes at room temperature.  Samples were inserted into disposable 
chambers which had been bored out to a diameter of 0.406 inches and 425 μL PPP was 
added.  Clotting was initiated with the addition of a 200 mM CaCl2 solution to a final 
calcium concentration of 6.0 mM.  Samples were analyzed using a Thromboelastograph 
Analyzer 5000 (Haemoscope, Niles, IL) for speed of onset of the clot, initial formation 
rate of the clot and maximum strength of the formed clot. 
 
2.5 Protein Immobilization 
2.6.1 Protein 1 via Carboxylic acid 
A 0.1 g / mL solution of 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride 
(EDC, Thermo Fisher Scientific, Rockford, IL) was prepared in a 0.1 M 2-(N-
Morpholino)ethanesulfonic acid (MES, Sigma Aldrich, St. Louis, MO) solution pH 4.5.  
500 μL of the EDC in MES solution was added to each sample and was allowed to react 
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at room temperature with shaking.  After 15 minutes, 500 μL of a 20 mg / mL N-
hydroxysulfosuccinimide (Sulfo-NHS, Thermo Fisher Scientific, Rockford, IL) in MES 
buffer and added to each sample’s solution.  After 30 minutes at room temperature, the 
solution was removed from each sample and 1 mL of a 1 mg / mL solution of protein 1 
prepared in phosphate buffered saline (PBS, pH7.2) was added to each PU samples from 
reaction 3 for 2 hours at room temperature.  Upon completion, the PU samples were 
washed with 2 mL of PBS per sample 2 x 30 minutes. 
 
2.5.2 Protein 2 via Oxirane 
Following the immobilization of protein 1, 1 mL of a 1 mg / mL solution of protein 2 
prepared in PBS was reacted for 24 hours at 4oC.  The samples were washed 2 x 30 min 
PBS, 2 x 30 minutes PBS +.05% Tween 20, 3 x 30 min PBS. 
 
Following final protein attachment the samples were stored in PBS at 4oC. 
 
2.6 Protein Analysis 
2.6.1 Protein Quantification by Bicinchoninic Acid Method 
Immobilized protein was quantified using the bicinchoninic acid (BCA) method.  Briefly 
samples were incubated with BCA solution and a copper sulfate solution (QPBCA kit, 
Sigma Aldrich, St. Louis, MO).  Incubation in the presence of protein reduces the copper 
which reacts with the BCA which was quantified by spectrophotometer.  Samples were 
incubated with 1 mL of BCA solution which was diluted with 1 mL of PBS (pH 7.2) for 
3 hours at 37oC or overnight at room temperature.  Protein concentrations were calculated 
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based upon a standard curve, points in triplicate, which was incorporated during every 
experiment.  Absorbance at 595 nm was taken by a microplate reader (Elx800, Bio-Tek 
Instrument, Clarkston, MI, USA). 
 
2.6.2 Protein Quantification by 125I Labeled Protein 
IgG and BSA labeled with radioactive iodine (125I, half life 60 days, MP Biomedicals, 
Solon, OH) were diluted in a 1:50 ratio to unlabelled protein and immobilized as 
described above.  Samples were thoroughly washed as described in the protein 
attachment protocol and the radioactivity measured using a LKB Wallac 1282 
Compugamma CS Universal Gamma Counter (Perkin Elmer, Waltham, MA). 
  
2.6.3 Immuno-Fluorescence 
Samples following protein immobilization, human IgG through the oxirane and BSA 
through the acid, were incubated with 1.5 mL of a 1:1000 dilution of anti-human IgG 
conjugated to FITC or a 1:100 dilution of anti-BSA conjugated to Texas Red fluorescent 
label overnight at 4oC.  Samples were washed with 2 mL PBS + 0.05% Tween 20 for 30 
minutes and repeated 3 times followed by washing with 2 mL PBS for 30 minutes and 
repeated 3 times to remove unbound antibodies.  Surfaces were developed using a Leica 
DM IL Fluorescent microscope. 
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Results 
3.1 Chemical Modification of PU 
 The overall scheme for the surface modification of PU surfaces and the further 
functionalization of PU-surfaces with the proteins of interest is schematically represented 
in figure 2.  Briefly, the PU surfaces were first reacted with LDA, followed by reaction 
with epibromohydrin to yield oxirane terminated surfaces.  The oxirane functionalized 
surfaces were further modified with aminovaleric acid to immobilize proteins via the 
pendant carboxylic groups.  The reaction with LDA and epibromohydrin was repeated to 
introduce a reactive oxirane group for the immobilization of protein-2.  PU or its variants 
(carboxyl-PU) has been modified, either on the surface or in bulk, to allow the attachment 
of biologically relevant molecules.  In most cases, the surface modifications have 
introduced active sites that allow for the immobilization of one protein per reactive site. 
Our studies seek to mimic the catalytic reaction that takes place on biological surfaces, 
which often requires proteins to be either co-immobilized on a single reactive site or 
anchored in a way such that the reactive pockets are in close proximity to catalyze 
biological reactions (figure 3).  The first and third steps of the developed synthesis are 
based upon the dibromo alkylation steps of Alferiev and Levy, however the synthesis was 
altered to be reacted across the solid-liquid interface.  This modification of the synthesis 
is made to be more suitable for manufacturing by allowing for modification of the 
material surface post modification.  This difference was also designed to prevent the 
modification of the bulk mechanical properties by limiting the modification only to the 
surface of the material and by preventing cross-linking of the polymer chains which can 
occur when using a symmetric extension. 
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3.2 Analysis of Modifications to PU 
3.2.1 Quantification of Epoxide on Surface 
 In order to quantify the concentration of oxirane groups added to the PU 
backbone, which is also a direct measurement of available reactive moieties, PU surfaces 
obtained at the end of reaction 1 and reaction 3 were assayed for total oxirane or epoxide 
groups and the values obtained are reported in figure 5. Reaction-1 and reaction-3 
introduced 6.71 x 10-3 mmol of oxirane groups/cm2 and 5.10 x 10-3 mmol of oxirane 
groups/cm2, respectively. At the end of reaction-2, a residual amount of 8.34 x 10-5 mmol 
of oxirane groups/cm2 were noted of PU surfaces, indicating a majority of the groups 
(99%) introduced in reaction-1 with amino-valeric acid to yield a reactive –COOH group. 
 
3.2.2 FT-Infrared Spectroscopy 
 The chemical modifications were characterized by using fourier transform 
infrared spectroscopy (FTIR).  Initial assignment of peaks for the spectra of modified PU 
samples produced only peaks assigned to the bulk materials due to the low concentration 
of surface groups in comparison to those of the bulk material, figure 6.  As a result the 
spectra were normalized to the greatest peak and compared for differences.  In the spectra 
for reaction 1 samples, figure 7, a strong new peak can be observed at 1200 cm-1 which is 
characteristic of species containing oxirane.  In the spectra for reaction 3, figure 8, a large 
broad peak can be found between 3100 and 3500 cm-1 attributed to the acid group arm of 
the bridge and a new peak can be found at the 1200 cm-1 attributed to oxirane arm of the 
bridge. 
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3.2.3 XPS Analysis 
 The synthesis was further confirmed through the elemental analysis and carbon 
bond analysis studied in XPS.  XPS is able to give better resolution of surface groups as it 
only characterizes to a depth between 10-250 Å (1-25 nm).[44]  The elemental analysis, 
figure 9 and 10, shows an increase in the relative oxygen concentration following 
reaction 1 and reaction 3 which corresponds to the addition of epibromohydrin and its 
oxirane species.  In addition a significant increase in nitrogen concentration can be seen 
with immobilization of 5-amino valeric acid through the oxirane formed in step 1 of the 
synthesis.  In examining the relative concentration of C1s, figure 11, it is important to 
note that this method is unable to distinguish between carbon oxygen species and carbon 
nitrogen species of similar bond type.  As we proceed through the first reaction and a 
large increase can be seen in at 286.7 eV corresponding to the addition of the first oxirane 
extension from the surface.  In reaction 2, there is a significant increase in the two acid 
bonding species corresponding to the addition of the amino acid.  There is a small 
decrease in the carbon oxygen / carbon nitrogen species which could be attributed to just 
a relative decrease in ratio due to the second step, or could be a result of oxirane opening 
without amino acid binding.  If a small number of oxirane are opening prior to reaction 
with the amino acid this could suggest that the percent yield calculation would be 
artificially high, figure .  This phenomena would not affect the final concentration of 
oxirane and total number of bi-dentate bridges formed, but instead would increase the 
percent completion of the final step of the synthesis.  The XPS bond concentration 
analysis of the third step again shows an increase in the concentration of carbon oxygen 
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bonds while still maintaining the concentration of acid groups, suggesting that the bi-
dentate bridge is formed and in the correct positions. 
 
3.3 Mechanical Testing 
 Samples were analyzed for stress at a linear strain rate and plotted as stress as a 
function of strain.  The initial slope was calculated as the intial modulus and charted as a 
function of the solvent used during the modification of the samples and shown in figure 
12.  Surface modification PU without impacting the bulk properties was a desired 
research goal, as a change in bulk properties may manifest as a decrease in the material 
properties of PU.  Thus as an initial step, reactions were conducted in THF, pure 
anhydrous hexane and 50:50 mixture of THF and hexane to investigate the effect (if any) 
of the solvent used on the mechanical properties of the material. As noted in figure-X, , 
samples that had been reacted in THF had a significant change in the modulus in contrast 
to samples reacted in pure hexanes.  This difference is attributed to the degree of 
absorption of the PU samples for the two solvent.   
 
3.4 Biocompatability 
3.4.1 Leachables 
 The in vitro biocompatibility of surface modified PU films at the end of reaction-
1, reaction-2 or reaction-3 prepared in the laboratory were evaluated to ascertain the 
impact, if any, of chemical crosslinkers or solvents used. While every step was taken to 
ensure the removal of reagents and solvents used in the modification steps, the impact of 
any potential leachables from the modified PU films was evaluated. The ability of 
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extracts or leachables, obtained from the incubation of modified PU surfaces in cell 
culture medium, to support growth and proliferation of fibroblasts is presented in figure 
13 and 14. Similar cell counts were noted between fibroblasts cultured fresh medium and 
leachates.  The absorbance from the cell viability test (MTT assay) on various PU films 
was calculated as a percentage of the control (cells on tissue-culture polystyrene, TCP). 
The viability of cells on the PU films was not significantly different from the cells on the 
TCP. The results show that the modified PU surface was not cytotoxic to the fibroblast 
cells, because the cell viability remained the same as the control after 3 days in culture. 
Cell viability in the range of 90–97% was routinely attained, indicating that modification 
is not cytotoxic and the modified PU samples maintained biocompatibility. 
 
3.4.2 Hemolysis 
 Hemolysis testing is the most common method to determine the 
hemocompatibility properties of biomaterials and was evaluated because erythrocytes are 
among the first cells that come into contact with foreign materials in the blood vessels.  
Damage of red blood cells (hemolysis) by contact with biomaterial surfaces was used as 
measure of the biomaterial incompatibility and was determined by spectrophotometric 
measurement of hemoglobin content. The results did not demonstrate any hemolytic 
effects of modified PU surfaces, with the average hemolysis of both PU’s under 2%. 
(figure 15) 
 
3.4.3 Thromboelastograph 
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Thromboelastography (TEG) is a method of testing the efficiency of coagulation in the 
blood and measures the changes in elasticity at all stages of the developing and resolving 
clot.  To evaluate the effect, if any, of the modified PU surfaces on the efficacy of 
coagulation, samples were studied by thromboelastography using platelet poor plasma 
(PPP).  The time taken to clot onset, kinetics of clot formation, and strength of the clot 
formed were evaluated for modified PU films and compared to non-modified films and 
shown in figure 16.  As noted in figure 17, no significant change was observed in the 
recorded times of initial fibrin formation (SP), time to clot initiation (R), or the strength 
of the clot formed using PPP, between control PU and modified PU samples. 
 
3.5 Protein Immobilization 
3.5.1 Quantification 
 While a variety of proteins can be immobilized of the modified PU surfaces 
developed is this study, to demonstrate the efficacy of protein attachment and offer proof-
of-concept, the following proteins were chosen as model proteins: BSA and hIgG. The 
ability of each arm of the reactive bi-dentate functional group to covalently bind protein 
was quantitatively analyzed.  The amount of covalently bound protein was quantified by 
two methods: a) a radiolabeled method in which 125I-labeled protein were immobilized 
and the surface adsorbed radioactivity was gamma counted and b) by a colorometic 
method that uses BCA to react with the available primary –NH2 groups and reported in 
figure 18. The sensitivity of the radioactive method and BCA method is in the range of 
picomoles and micromoles of adsorbed protein, respectively.  Values obtained by the 
independent methods are in good agreement. The total amount of covalently anchored 
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protein in g/cm2, which includes attachment on both the bi-dentate arms, was estimated 
to be in the range of 0.3 – 0.24 µg / cm2.  Surface adsorbed protein density when protein 
was covalently attachment via one of the bi-dentate arms was estimated to be in the range 
of 0.1 to 0.16 µg / cm2.  These concentrations are comparable to reported values of 
protein immobilization onto PU supports via incorporated carboxylic extensions or by 
plasma modification. 
 
3.5.2 Immunofluorescence 
To visualize surface adsorbed proteins on modified PU surfaces, eitherhuman IgG (hIgG) 
and bovine serum albumin (BSA) were first covalently attached through the desired 
mechanism and the surface bound protein was detected using a fluorescently tagged 
antibody.  Representative fluorescent panels are depicted in figure 19. Panel-A, shows 
modified PU films that were sequentially exposed to FITC-labled anti-human IgG and 
Texas-Red labeled anti-human BSA. The lack of fluorescent signal indicates the poor-
reactivity of the secondary antibodies with the modified-PU films.  Panel-B, shows 
modified PU films with covalently immobilized BSA via the –COOH functionality (end 
of reaction-2) and exposed to FITC-labled anti-human IgG and Texas-Red labeled anti-
human BSA. The red color gives a qualitative measure of the presence of covalently 
immobilized BSA or an indirect measure of the success of the reaction-2 and its further 
reaction with BSA.  Panel-C, shows modified PU films with covalently immobilized 
hIgG via the oxirane functionality (end of reaction-3) and exposed to FITC-labeled anti-
human IgG and Texas-Red labeled anti-human HSA. The green color gives a qualitative 
measure of the presence of covalently immobilized hIgG or an indirect measure of the 
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success of the reaction-3 and its further reaction with hIgG.  Panel-D, shows modified PU 
films with both BSA and hIgG covalently immobilized hIgG via the bi-dentate 
functionality and exposed to FITC-labled anti-human IgG and Texas-Red labeled anti-
human HSA. The presence of both the red and the green color gives a qualitative measure 
of the success of the reaction-2 and reaction 3 and its further reaction with BSA and 
hIgG, respectively.
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Discussion 
 The combination of toughness, durability, biocompatibility, and biostability of 
polyurethane (PU) compositions has led to the usage of segmented PU in medical 
devices.[56] PU also contains essential features for a successful vascular prosthesis that 
has a low friction flow surface and optimal mechanical elastic properties similar to 
natural vessel.[57, 58]  Thus biomedical grade PU was chosen a biomaterial surface.  
Previous methods have described methods of modification for the immobilization of 
proteins and biomolecules have included bulk and surface functionalizations that are 
limited to a single immobilized molecule.  In more complex systems, multiple molecule 
immobilization may be required.  The chemistry described above allows for the creation 
of bifunctional bridge extended from the surface which has been confirmed through FTIR 
and XPS spectroscopy.  By utilizing this bifunctional bridge, two proteins can be attached 
to a single point on the materials surface in an enzymatically relevant scale.  In this 
method, the attachment can be controlled as to which functional end of the bidentate 
bridge the protein is covalently bonded to, demonstrated in figure 19.  Despite the 
addition of two proteins to the surface, each protein was immobilized at approximately 
the same concentration, figure 18, and a concentration similar to that of other PU 
immobilization methods, figure 1.   Also of interest is that following modification, the PU 
samples were able to maintain the blood compatibility, figures 15-17, which makes the 
polymer of interest for vascular applications.  By incorporating tetrahydrofuran (THF) as 
a solvent in the first and third step of the synthesis there was a significant lowering of the 
elastic modulus of the modified material as can be observed in figure 12.  The choice of 
solvent was also changed after observing the effects solvent has on the mechanical 
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properties.  The use of THF as a solvent for reactions using lithium diisopropyl amide 
(LDA) or sodium borohydride is common because the lone pairs of the bound oxygen 
help to stabilize the transfer of the metal during the reaction.  However, samples which 
were reacted in pure THF were damaged during the wash steps in which THF has been 
absorbed into the polymer sample was removed using with deionized water.  Ultimately 
these samples were deformed and failed under reduced loads, as can be observed in 
tensile testing data in figure.  The THF solvent did serve two other important purposes in 
the synthesis, first it was able to remove any impurities that existed on the surface of the 
fabricated surfaces which can be observed by the near complete removal of all silicon 
impurities, which we speculate as being introduced by the casting of films on glass 
surfaces, by samples reacted with THF and only partial removal in samples reacted in 
hexanes alone.  Secondly it allowed the samples to swell which created more absorbance 
of the reactants onto the surface to increase the yield of the reaction over samples reacted 
in hexanes alone.  While the use of THF did reduce the modulus as compared to control 
PU, the samples modified in a 50/50 mixture were consistent with that of human 
aorta[59] and greater than that of veins used as arterial xenografts[60]. 
 This new method of modification leads itself to several potential applications.  
Over the past two decades surface modifications have been made to the surface of 
polymer implants in an effort to passivate the surface, reducing the body’s response to the 
material.  However in recent years, more emphasis has been put on developing a 
biomimetic surface which is designed to interact with the body in a manner similar to 
natural tissue.  The design of these surfaces is engineered to mimic the chemical 
composition of a cell membrane, the catalytic events on the cell surface, topography of 
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the natural surface, mechanical response of a tissue to a stimulus, or direct the adhesion 
and differentiation of cells.  This has been especially evident in the development of 
suitable blood contacting surfaces for potential implants.  Initially these surfaces were 
modified to change hydrophilicity or charge density before being modified with 
endothelial cell membrane groups such as heparin or thrombomodulin in first attempts to 
mimic the natural nonthrombogenic nature of endothelial cells.   Due to the complexity of 
the coagulation pathways, current research is being conducted on the addition of multiple 
surface groups and blood proteins to inhibit the multiple aspects of clotting.  In some 
studies, blood proteins such as albumin are used to passivate the recognition of the 
surface as foreign while coupling the surface coating with membrane molecule such as 
prostacyclin or heparin.  In other attempts to create mimicking surfaces, a mixture of two 
membrane molecules such as heparin and thrombomodulin, are immobilized onto the 
surface of the material.  Another technique used is to mimic the catalytic events which 
occur on the surface of endothelial cells such as the production of nitric oxide and 
inhibition of thrombin.  However in all of these systems the coimmobilization of two 
different groups, the concentration and distribution on the surface are unable to be 
controlled.  What is more of a concern is that in many of these cases the immobilization 
steps proceed sequentially using coupling chemistries which could couple one protein to 
the other damaging the first protein attached.  In this case the damaged protein has the 
potential to unfold, losing the anti-thrombogenic qualities and instead becoming a point 
for the initiation of clotting.  Coimmobilization via the bidentate bridge eliminates both 
of these concerns.  In this method, the two proteins have equivalent distribution due to 
the tied immobilization site, and grafting the second protein to the first is eliminated by 
 38
conducting the fast coupling reaction first and a slow nucleophilic reaction second.  
Because the nucleophilic reaction proceeds through a oxirane surface group not found on 
proteins or biomolecules, it is impossible to create the protein-protein grafting.  Instead 
should a failure occur, it would be attachment of a single protein to multiple points of the 
surface. 
 The surface modification also provides the potential to activate enzymatic 
processes requiring two substrates.  This process can be seen in the coagulation system in 
the activation of the anticoagulant Protein C (PC).  In the activation of PC, a complex 
between thrombomodulin and thrombin is formed, which then clips the zymogen PC 
creating activated Protein C (aPC).  In this example both thrombomodulin and thrombin 
could be immobilized through the bidentate functional group which could cooperatively 
activate PC.  This process could also be designed in a system which more closely models 
in vivo aPC production by immobilizing thrombomodulin with endothelial protein C 
receptor (EPCR) a membrane protein which aids in the transport of PC to the membrane 
surface for activation.  In this system, the kinetics of the catalytic surface are modified by 
changing transport characteristics of the PC, the rate limiting step of the anticoagulent’s 
activation. 
 Endothelialized surfaces offer the potential of perfectly mimicking the 
compatibility of native blood vessels.  Development of these materials has shown the 
need for two components, a point of attachment for the cell and a stimulus maintain the 
cells phenotype.  While the attachment point can be as simple as a dimpled surface, the 
most successful have been the attachment of peptides which contain sequences derived 
from extracellular matrix proteins.  The stimulus used to direct or maintain the phenotype 
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has varied between chemical and mechanical stimuli.  For endothelial cells and their 
progenitors, the most common chemical stimulus is vascular endothelial growth factor 
(VEGF).  Since VEGF acts through a receptor mediated process, its coimmobilization 
with a cell anchoring peptide can lead to proper attachment, spreading and phenotype.  
Another common stimulus is shear mechanical force of blood over the cell layer.  While 
the laminar flow over the surface is needed for proper spreading, prior to the cells 
forming a complete monolayer, small clots can form on the surface in areas where cells 
did not properly attach.  These thrombi can lead to the formations of eddies which disrupt 
the flow over the cells leading to improper remodeling of the surface.  Should heparin or 
a similar anticoagulant be immobilized onto the suface with a cell binding peptide, the 
surface induced thrombi could be prevented leading to a more properly formed 
endothelialized layer.  Thus in the present study, we were motivated to generate 
biocompatible surfaces that would enable the immobilization of two biomolecules or 
moieties per site of activation. 
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Conclusions: 
 With the growing development of biomimetic surfaces, methods of controlled 
coimmobilization of proteins onto surfaces have been studied.  To date, these methods 
have been limited to self assembled monolayers, whose mechanical properties do not 
match those of the native tissue.  As a result there is a need for a method to pattern 
immobilize proteins or biomolecules onto a polymer surface. 
 We have demonstrated a method to create a bidentate functional group extended 
from the surface of polyurethane which does not alter the biocompatibility of the surface.  
Using this method, we have demonstrated that by using the bidentate functional group we 
can control to which terminal of the bridge a protein is attached and that the 
concentration of each protein bound to the surface is similar to concentrations of proteins 
immobilized by other methods.  Finally, we have shown that after modification the 
sample’s mechanical properties are comparable to native tissue suggesting that the 
synthesis can be used for future design of biomimetic materials.
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Reference Protein / Biomolecule 
Method of 
Addition Concentration 
Nojiri ASAIO Trans 1988 Heparin Isocynate extension 0.65 µg / cm2 
Lui J Biomed Mat Res 1993 (Insulin / transferrin) + collagen 
Plasma 
Ammonia 
Insulin 0.31 
µg/cm2 Trans 0.33 
µg/cm2 Coll 0.36 
µg/cm2 
Kishda Biomaterials 1994 Thrombomodulin hydrolysis <1 µg/cms 
Lee J Biomed Mat Res 1996 Collagen carboxy PU 24 µg /cm2 
Phaneuf J Biomat App 1997 BSA / Hirudin carboxy PU 300 ng / cm2 
Bae Biomaterials 1998 PEO / Heparin/ Acrylic Acid Plasma O2  
AA 0.47µmol/cm2 
PEO 42 nmol/cm2 
Hep 1.3 µg / cm2 
Phaneuf Artificial Organs 1998 BSA / Hirudin carboxy PU 184 ng /cm2 
Huang J Biomed Mat Res 1998 Collagen carboxy PU 25 µg / cm2 
McClung J Biomed Mat Res 
2000 Lysine Photo 3.2 nmol / cm2 
Van de Velde Biotech Bioeng 
2000 
Peroxidase + 
Glucose Oxidase 
Entrapment 
during 
polymerization 
NA 
Aldenhoff J Biomed Mat Res 
2001 Persantin UV 20 nmol / cm2 
Alferiev J Poly Sci 2001 Bisphophonate 
dibromo 
extension 
carbamate 
nitrogen  
0.09 mmol / g bulk 
mod 
Alferiev Biomaterials 2002 dansyl cysteine 
thiol extension 
carbamate 
nitrogen  
0.45mmol / g bulk 
mod 
Hsu Artificial Organs 2003 RGD containing Protein 
gelatin entraped 
polymer NA 
Yuan J Biomat App 2003 Sulfobetamine Isocynate extension NA 
LV J Mat Sci Mat in Med 2004 Acrylic Acid / Sulphonic Acid Plasma O2  NA 
Alferiev Biomacromol 2006 Heparin 
dibromo 
extension 
carbamate 
nitrogen  
1.11 µg / cm2 
Du J Biomed Mat Res 2007 AT3 / Heparin AIBN off PUU NA 
Aksoy J Bioact Compat Poly 
2008 Heparin Plasma O2 / AA NA 
Sartori Reac and Funct Poly 
2008 
Acrylic Acid / 
Gelatin / polylysine Plasma Argon NA 
 
Figure 1. Covalent immobilization of biomolecules onto a Polyurethane Support 
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Description of the method of modification, the molecule immobilized and the relative 
concentration of the immobilized molecule for biologically active polyurethane surfaces. 
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Figure 2.  A schematic representation of the proposed three step chemical 
modification to produce bidentate bridge functional group on a solid polyurethane 
surface.  Reaction 1 enables the addition of the first reactive oxirane moiety to the 
secondary nitrogen incorporated in the carbamate subunit of the PU backbone.  The 
addition of the reactive carboxylic acid branch of the bidentate bridge is achieved in 
reaction 2.  Reaction 3 enables the addition of a reactive oxirane functional group to 
complete the bidenate bridge. 
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Figure 3. Sequential Immobilization of Proteins. Chemical representation of the 
sequential immobilization of two proteins onto polyurethane modified with the bidentate 
functional group.  The pendant –COOH moiety will be first reacted with EDC/NHSS to 
generate a reactive ester and protein-1 will react via –NH2 groups to forma stable amide 
bond. Protein-2 will be immobilized via the ring-opening of the oxirane moiety. 
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Figure 4. A schematic of the sequential immobilization strategy.  Characterization of 
bidentate functional group and specifically the methods of attachment of each protein to 
the bridge. Protein-1 can be anchored via a nucleophilic reaction and protein-2 can be 
anchored via a coupling reaction. 
.
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Average 
mmol of 
oxirane / cm2 
Standard 
Deviation 
Percent 
Completion 
Reaction 1 6.71E-03 1.39E-03   
Reaction 2 8.34E-05 1.15E-04 98.8 
Reaction 3 5.10E-03 1.44E-03 76.1 
 
Figure 5. Concentration of Oxirane groups on the Polyurethane Surface 
Concentration of oxirane groups on the surface of polyurethane was calculated by 
titration following the ring opening reaction with 1.3 M sodium thiosulfate solution.  
Percent completion is calculation based upon number of oxirane created (Reaction 3) or 
lost (Reaction 2) in comparison to the previous reaction. Samples were analyzed in 
duplicate from a minimum of three batches. 
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Figure 6. FT-IR Analysis of Polyurethane Samples. 
FT-IR spectra of control samples of Chronoflex AR polyurethane (A) and PU modified 
through Reaction 1 (B), Reaction 2 (C), and Reaction 3 (D).  No new peaks were able to 
be observed through the modifications due to the low concentration of functional groups 
formed on the surface in comparison to the chemical groups found in the bulk polymer.  
Peaks at 2300 cm-1 can be disregarded as carbon dioxide. 
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Figure 7. Differences of FT-IR Spectra of PU Following Reaction 1 
Differences of FT-IR spectra of PU samples modified through Reaction 1 and spectra of 
unmodified Chronoflex AR PU.  The formation of a strong new peak can be observed at 
1200 cm-1 which is characteristic of species containing oxirane functional groups.  Peaks 
at 2300 cm-1 can be disregarded as carbon dioxide. 
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Figure 8.  Differences of FT-IR Spectra of PU Following Reaction 3 
Differences of FT-IR spectra of PU samples modified through Reaction 3, now 
containing the entire bidentate functional group and spectra of unmodified Chronoflex 
AR PU.  The formation of a large broad peak can be found between 3100 and 3500 cm-1 
attributed to the acid group arm of the bridge and a new peak can be found at the 1200 
cm-1 attributed to oxirane arm of the bridge.  The decrease in the relative strength of the 
oxirane peak is attributed to the percent yield of the modification.  The peak at 2300 cm-1 
can be disregarded as carbon dioxide. 
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Sample   C O N Si Ca F 
                
Control PU   68.5 18.9 0.7 11.4 0.5 N/D 
                
Reaction 1 Hexane   71.7 21.2 1.7 4.7 0.2 0.6 
Reaction 2 Hexane   69.2 21.5 2.9 5.0 N/D 1.5 
Reaction 3 Hexane   66.9 23.6 3.0 4.5 N/D 1.9 
                
Reaction 2 THF   75.0 22.3 1.7 1.1 N/D N/D 
Reaction 3 THF   75.5 22.1 1.6 0.6 N/D N/D 
  
Figure 9. Elemental Analysis of Polyurethane Surface by XPS 
 
Elemental analysis of control Chronoflex AR PU films and films modified in hexanes or 
THF by XPS.
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Sample   C O N 
          
Control PU   77.8 21.5 0.8 
          
Reaction 1 Hexane   75.8 22.4 1.8 
Reaction 2 Hexane   73.9 23.0 3.1 
Reaction 3 Hexane   71.6 25.2 3.2 
          
Reaction 2 THF   75.8 22.5 1.7 
Reaction 3 THF   76.1 22.3 1.6 
 
Figure 10. Elemental Analysis of Polyurethane Surface by XPS without Silicon 
Contamination 
 
Elemental analysis of control Chronoflex AR PU films and films modified in hexanes or 
THF by XPS.  Elemental percentages were recalculated without silicon impurity.
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    Bond Energy eV 
Sample   285.0 286.7 288.7 290.6 
            
Control   89.9 6.9 2.2 1.1 
Reaction 1   69.5 21.7 2.3 1.3 
Reaction 2   68.7 18.8 7.1 5.4 
Reaction 3   65.6 21.7 7.6 5.0 
            
Associated 
Bonds   C-C/C-H C-O C-(C=O)-O O-(C=O)-O
 
Figure 11.  C1S Percentage by Bonding Energy 
 
Percent of carbon bonds measured at each bond energy by XPS in control and modified 
polyurethanes. 
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Figure 12. Mechanical Analysis of Polyurethane Samples. 
 
Initial modulus of control and modified polyurethanes as a function of solvent system 
used during modification.  Modulus was determined in tension with a constant strain rate 
of 0.5 N / min at 37oC.  Sample modulus was normalized to the average modulus of 
control unmodified Chronoflex AR.  Average modulus of control, 8.695 ± 0.319 MPa.  
Error bars represent one standard deviation. 
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Figure 13.  Leachables Analysis of Modified Polyurethanes 
 
Cell count of fibroblasts following culture on tissue culture plates with DMEM media 
containing leachables extracted from unmodified polymer films and modified 
polyurethanes.  No significant difference was observed between fibroblasts cultured in 
media incubated with unmodified PU and modified PU.
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Figure 14.  Cell Viability Assay 
 
The viability of fibroblasts grown in media incubated with polyurethane samples.  MTT 
assay demonstrated no significant difference in cells grown in media incubated with 
control PU and modified PU samples. 
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% Hemolysis Average Standard 
Deviation 
Unmodified Polyurethane 1.32 0.333 
Samples through Reaction 3 1.72 0.253 
 
Figure 15.  Hemolysis of Modified Polyurethane 
 
Percent hemolysis of fresh whole blood following incubation with control Chronoflex 
AR and chemically modified PU samples.  Five individual samples from 2 independent 
batches were tested and normalized to controls from their respective films. 
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Figure 16. Thromboelastograph Analysis of Blood Compatibility of Polyurethane 
Samples. 
 
Measure of the clotting characteristics of control Chronoflex AR and modified PU with 
platelet poor plasma by thromboelastograph.  The chart tracks the time to clot initiation 
and the formation of the clot until it reaches its maximum amplitude.     
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Thromboelastograph Values 
    SP(sec) R(sec) K(sec) MA(mm) 
            
Average 350.0 388.3 220.0 34.6 
Unmodified Std 
Deviation 31.2 34.0 70.9 3.6 
            
Average 346.7 381.7 148.3 35.4 
Reaction 1 Std 
Deviation 63.3 63.3 35.5 2.9 
            
Average 326.7 408.3 185.0 33.9 
Reaction 3 Std 
Deviation 52.5 20.2 65.4 1.0 
 
Figure 17. Thromboelastograph Values 
 
Measure of the clotting characteristics of control Chronoflex AR and modified PU with 
platelet poor plasma by thromboelastograph.  No significant change was observed in the 
recorded times of initial fibrin formation (SP), time to clot initiation (R), the kinetics of 
clot formation (K) or the strength of the clot formed (MA) using PPP, between control 
PU and modified PU samples. 
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125I Labeled Protein Bicinchoninic Acid 
Proteins 
Attached µg / cm2 Standard Deviation µg / cm
2 Standard Error 
1 Protein 
via Acid 0.165 
Calculated 
from Other 
Values 
0.118 0.037 
1 Protein 
via 
Oxirane 
0.133 0.064 0.19 0.05 
2 Proteins 0.298 0.037 0.242 0.041 
 
Figure 18. Quantification of Protein Immobilized via the Bidentate Functional 
Group. 
 
Quantification of protein immobilized onto each site of bidentate functional group.  
Protein concentration of covalently bound protein was measured by the immobilization of 
125I labeled IgG and by reaction with bicinchoninic acid.  Four individual samples from 3 
independent experiments were tested and normalized to controls from their respective 
films. 
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Figure 19. Qualitative analysis of protein immobilization via the bidentate 
functional group. Samples following protein immobilization, human IgG 
through the oxirane and BSA through the acid, were incubated with 1.5 mL of a 
1:1000 dilution of anti-human IgG conjugated to FITC or a 1:100 dilution of anti-
BSA conjugated to Texas Red fluorescent label overnight at 4oC.  Samples were 
washed with 2 mL PBS + 0.05% Tween 20 for 30 minutes and repeated 3 times 
followed by washing with 2 mL PBS for 30 minutes and repeated 3 times to 
remove unbound antibodies.  Surfaces were evaluated using a Leica DM IL 
Fluorescent microscope.
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Chapter 2 
Mechanical Analysis of Polyurethane Modified for Sequential 
Protein Immobilization 
 
 
 66
Absrtact 
 
Material elasticity and compliance have been studied for many years as they have been 
linked with the one of the main forms of failure, the formation of an intimal hyperplasia 
(IH).  IH, a cellular formation composed of smooth muscle cells, is formed in areas where 
the blood flow, specifically the wall shear stress, has changed.  Over time, IH found in 
vascular grafts has been linked to a mismatch of the material compliance of the synthetic 
graft to the native tissue causing an augmentation of the blood flow pattern.  
Polyurethane (PU) is a polymer used in the making of experimental vascular grafts whose 
compliance and elasticity have been molded to exactly match that of a vessel.  However 
PU’s use in vascular system is limited by its blood compatability.  This chapter will 
examine the mechanical properties of control PU and compare it to chemically modified 
PU developed in chapter 1 which will allow for the immobilization of proteins to increase 
the polymer’s blood compatibility.  
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Introduction 
 Early design of vascular grafts were created from materials which were common 
and shown to be nontoxic such as polyesters (PE) and polytetrafluoroethylene (PTFE) 
with little regard to the mechanical properties of the material past long term durability, 
however a low 2 year patency rate was found for artificial grafts produced from these 
materials.[1]  Over time it was discovered through explant studies that animal models 
implanted with these grafts showed an abnormal growth at the distal end of the graft site 
known as intimal hyperplasia (IH).[2-6] 
 The intima is the inner most of three layers which compose the blood vessel and 
is composed of the endothelial cell monolayer and a basement membrane formed by 
collagen (type IV), lamin and proteoglycans.[4, 7]  Naturally as they age and 
incorporated in the diseases of hypertension and arthersclerosis there is a thickening of 
this layer created by the migration of vascular smooth muscle cells (VSMC) and 
production of their extracellular matrix by these cells.  It is this growth which is referred 
to as IH.  Abnormal IH formation is seen as a result of injury to the vessel, inflammation 
or an increased mean wall stress.[4]  It is through an increased mean wall stress in which 
artificial grafts are believed to create IH. 
 Blood vessels are considered viscoelastic, meaning that they are not perfectly 
elastic, instead over time vessels will lose some of their mechanical properties due to 
stress relaxation and creep.[8-10]  Like other viscoelastic materials, vessels do exhibit 
some elastic behavior which allows for expansion under systolic pressure.  The degree to 
which they expand as well as the ability to contract back to their original are related to 
the mechanical properties of elastic modulus or stiffness and the compliance.[8, 9]    
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Modulus is the relationship of stress done on a material to the resulting strain of the 
material with the linearity of the response being related to the elasticity of material.  The 
compliance is normally defined as the inverse of the elastic modulus of a sample, 
however for vascular mechanics this relationship is normally defined as the change in 
volume of the vessel to the change of pressure during a pulsed experiment.[8, 9]  As a 
result of the expansion of the vessel under cardiac cycling, the modulus and the 
compliance affect both the flow rate and the flow geometry of the blood.[11]  It is these 
factors which are believed to cause the change in the wall shear rate which leads to the 
development of IH.[4-6] 
 This phenomena, which is normally referred to as compliance mismatching[6, 12, 
13], has lead researchers to change the internal diameter of the grafts to maintain the 
native flowrate.  While this technique has corrected the linear flowrate and the average 
wall shear rate, it is not able to create the correct flow geometry.[14, 15]  In addition the 
change in the internal diameter has lead to the occlusion from fibrous buildup for grafts 
where the diameter in decrease or the formation thrombo-emboli in grafts whose diameter 
was increased.  Vein cuffing of polymer grafts is another method which has been 
investigated to try and correct the issue of compliance mismatch.  In this case the 
vascular graft has a portion of harvested vein attached to the distal end of the graft.  In 
doing this the vein which tends to be more compliant that arteries absorbs much of the 
pressure of the increased flow.[16-18]  This method does not completely rectify the 
problem of flow geometry and also presents the issue of artificial vascular grafts being 
used largely for patients whose veins are damaged through disease that they are not 
suitable for transplantation.  Other research has been conducted on the formation of grafts 
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using multilayer constructs.[19]  By creating multilayer constructs, where the different 
layers have different mechanical properties, researchers have attempted to mimic the 
multiple phases of a blood vessel.  These methods have included using a type of stent 
placed around a vein to restrict its expansion or the formation of layers with different 
porosities or crosslinking and have produced grafts of varying success.[20] 
 The most promising vascular grafts have been produced using polyurethane.  
Polyurethane being a copolymer can have many of its mechanical properties tailored to 
the biological and mechanical requirements.  As a result polyurethanes naturally have 
mechanical properties on the same order as those of native arteries.  These mechanical 
properties have been coupled with different molding techniques, such as the 
incorporation of ridges on the outside of the graft to limit expansion, to create grafts 
whose compliance is identical to that of the artery which is being replaced.[21-23]   
 While the initial compatibility of the vascular graft has been focused on in the 
design, the mechanical properties of polymer grafts also influence the long term 
durability of a potential implant.  Until recently, artificial grafts have mainly been studied 
for 2 year patency, however this is due more to the development of IH or fibrous 
occlusion than actual failure of devices.  In some cases it was found that certain polymers 
were susceptible to biodegradation, this was specifically the case of polyester urethane 
and polyurethane urea.  Newer versions of polycarbonate urethanes have proved much 
more resistant to the hydrolysis which caused device failure.[21]  Larger durability issues 
stem from the viscoelastic nature of polymers and the stress relaxation and creep 
phenomena which alter the mechanical properties over time and could eventually lead to 
a failure.[24]  Polyurethane used in the construction of heart valves have shown the 
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ability to withstand 10 to 12 years worth of cycling in accelerated fatigue tests[25, 26] 
suggesting that should their blood compatability be controlled, grafts constructed from 
these polymers could be suitable for long term implantation. 
 This study seeks to determine the effects on the long term durability of 
polyurethane which has been surface modified to improve upon its biocompatibility.  In 
this method, polyurethane films were modified in the precut solid state form across the 
solid-liquid interface in an effort to reduce the effect on the bulk mechanical properties.  
The modified samples will be characterized by the initial modulus and by total stored 
energy of the polymer sample prior to and following fatigue cycling as a function of the 
solvent used during the modification.  The effects of the fatigue on the mechanical 
compliance of the polymer samples were also studied do to the importance of compliance 
for developing vascular grafts.  We predict that modified samples following fatigue will 
show no significant difference between modified samples and control polyurethane 
samples in either the stored energy or the compliance.
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Methods 
 Chronoflex AR medical grade polyurethane was generously provided as a gift 
from Cardiotech Inc. (Cambridge, MA).   
 
2.1 Preparation of Surface Bridge 
 Reaction 1 will enable the addition of the first reactive oxirane moiety to the 
secondary nitrogen incorporated in the carbamate subunit of the PU backbone.  The 
addition of the reactive carboxylic acid branch of the bidentate bridge is achieved in 
reaction 2.  Reaction 3 enables the addition of a reactive oxirane functional group to 
complete the bidenate bridge.  Subsequent paragraphs will provide the experiment details 
of the surface modification. 
 
2.1.1 Reaction 1  
Solution cast polyurethane films were cut into 0.3 x 3.0 cm samples with an average 
weight of 30 mg.  Under an inert atmosphere, approximately 1 gram of polyurethane was 
added to 75 mL tetrahydrofuran (THF, HPLC Grade 99.9%, Sigma Aldrich, St. Louis, 
MO) mixed with 75 mL hexanes (ACS Grade, Sigma Aldrich, St. Louis, MO) and the 
temperature of the mixture reduced to -5 oC using an isopropyl alcohol ice bath.  0.5 mL 
epibromohydrin and 0.5 mL of a 2.0 M lithium diisopropyl amine (LDA, Sigma Aldrich, 
St. Louis, MO) in THF were added to the mixture and the reaction was allowed to 
proceed for 2.5 hours with stirring.  Upon completion, the LDA, THF solution was 
removed from the PU samples and neutralized with a 3% (V/V) acetic acid solution.  The 
PU samples were washed with 150 mL deionized water for 30 minutes and repeated 3 
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times to remove excess THF / Hexane solution.  Residual solvent was removed under 
reduced pressure, P < 0.3 Torr for at least 6 hours. 
 
2.1.2 Reaction 2  
PU samples from reaction 1 were added to a 0.02 M 5-amino valeric acid (Sigma 
Aldrich, St. Louis, MO) in water.  The samples were allowed to react at room 
temperature for 24 hours with stirring.  Samples were washed with 150 mL deionized 
water for 30 minutes and repeated 3 times.  All absorbed water was removed by 
evaporation under reduced pressure, P < 0.3 Torr for at least 6 hours. 
 
2.1.3 Reaction 3 
Under an inert atmosphere, PU samples from reaction 2 were added to a 150 ml mixture 
THF  and hexanes (50/50 by volume) and the temperature of the mixture reduced to -5 oC 
in an isopropyl alcohol ice bath.  0.5 mL epibromohydrin and 0.5 mL of a 2.0 M lithium 
diisopropyl amine (LDA, Sigma Aldrich, St. Louis, MO) in THF were added to the 
mixture and the reaction was allowed to proceed for 2.5 hours with stirring.  Upon 
completion, the LDA, THF solution was removed from the PU samples and neutralized 
with a 3% (V/V) acetic acid solution.  The PU samples were washed with 150 mL 
deionized water for 30 minutes and repeated 3 times to remove excess THF / Hexane 
solution.  Residual solvent was removed under reduced pressure, P < 0.3 Torr for at least 
6 hours.  Samples were at room temperature until use. 
 Samples described in the above were prepared using a 50 / 50 by volume solvent 
mixture of THF and hexanes for reaction 1 and reaction 3, however similar reactions 
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were conducted using pure THF or pure hexanes as a solvernt.  Unless otherwise noted, 
all data described is for samples modified in a mixture of the two solvents. 
 
2.2 Mechanical Analysis 
2.2.1 Tensile Testing 
Samples were cut to size and reacted as described above in THF, Hexane or a mixture of 
the two solvents (50% of each by volume).  Samples were analyzed for stress at 37 C 
under a constant strain rate of 0.5 N/min to a strain of 5 N or failure using DMA Q800 
(TA Instruments, New Castle, DE).  The data was the analyzed as stress as a function of 
strain.  The initial elastic modulus was found by calculating the slope of the data over the 
initial linear region.  
 
2.2.2 Energy Loss Fatigue Testing 
Cut samples were prepared through reaction 3 as described above.  Samples were 
mounted in tension in a DMA Q800 (TA Instruments, New Castle, DE) and equilibrated 
for 5 minutes at 37 C.  Samples had their energy measured in an initial stess strain curve, 
1-25% strain with a 5% strain/min rate and an unloading at the same rate.  The samples 
were then fatigued from 1-12.5% strain at a strain rate of 250 %/min and unloading at the 
same rate for 500 cycles.  Samples had their energy measured in a second stess strain 
curve, 1-25% strain with a 500 % strain/min rate and an unloading at the same rate. The 
samples were then fatigued from 1-25% strain at a strain rate of 500 %/min and 
unloading at the same rate for 500 cycles.  Samples had their final energy measured in a 
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stess strain curve, 1-25% strain with a 5% strain/min rate and an unloading at the same 
rate.   
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Results 
 
3.1 Tensile Testing 
 Samples were analyzed for stress at a linear strain rate and plotted as stress as a 
function of strain.  The initial slope was calculated as the intial modulus and charted as a 
function of the solvent used during the modification of the samples and shown in figure-
1.  Surface modification PU without impacting the bulk properties was a desired research 
goal, as a change in bulk properties may manifest as a decrease in the material properties 
of PU.  Thus as an initial step, reactions were conducted in THF, pure anhydrous hexane 
and 50:50 mixture of THF and hexane to investigate the effect (if any) of the solvent used 
on the mechanical properties of the material. As noted in figure-1, samples that had been 
reacted in THF had a significant change in the modulus in contrast to samples reacted in 
pure hexanes.  This difference is attributed to the degree of absorption of the PU samples 
for the two solvent.   
 
3.2 Energy Loss Fatigue Testing 
 Samples were analyzed for stress at a linear strain rate prior to and following two 
sets of mechanical cycling using a method modified from Beatty et al.[27].  The data was 
analyzed by integrating the area beneath the stress – strain curve, figure 2, to calculate the 
stored energy of the sample reported in figure 3.  Despite the difference seen in the initial 
modulus in the prior experiment, there was no significant change in the stored energy 
prior to or following fatigue cycling for modified samples as compared to control 
samples. 
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 During the same experiment the effect of mechanical cycling on the compliance 
of the polyurethane samples was studied.  The data was plotted as compliance as a 
function of stress, figure 4-6, and the slope of the curve and minimum calculated, figure 
7.  Again, while significant differences were seen prior to and post fatigue, no significant 
change was found between samples which had been modified in either solvent and the 
control films provide from the manufacturer. 
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Discussion 
 The design of artificial small diameter vascular grafts has often focused on the 
blood compatability of the materials used due to low patency rates as a result of 
occlusion.  However, in vivo models have shown that the mechanical properties of 
vascular grafts also have a direct effect on graft patency through compliance mismatching 
leading to the development of IH.[11]  Following this discovery of this relationship, 
several mechanical properties including elasticity, compliance and durability have been 
taken into consideration during design.  Because of their natural compliance and 
biocompatability, polyurethanes (PU) have become of interest for vascular implants.  
Methods have actually been designed to create vascular grafts with the exact compliance 
of the vessel they are replacing using Chronoflex PU, the same medical grade polymer 
used in this study.[21, 23]  There is still a need to modify the surface properties of PUs to 
help prevent thrombosis and prevent occlusion of a potential graft, however it is also 
necessary for any modification to leave the bulk mechanical properties intact. 
 Following modification, PU samples were characterized by the initial modulus as 
a function of the solvent system used for modification.  While a significant change was 
seen for samples modified in the pure THF or a 50/50 (v/v) mixture of THF and hexanes, 
the change in modulus was not great enough to prevent the use of the material in the 
design of vascular grafts as the modulus of the material is on the same order of magnitude 
as that measured in vascular tissues.  Modification of the PU in pure hexanes did not 
show a change in the samples modulus as compared to control samples, however as was 
discussed in the previous chapter, use of THF aides in the swelling of samples during 
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modification and the removal of impurities from the surface of experimental samples left 
from initial processing. 
 The change in the initial modulus suggested a modification of the bulk properties, 
which could alter the long term durability of a created graft.  To examine this possibility, 
the stored energy of the sample, as defined as the area beneath the stress strain curve, was 
measured prior to and following mechanical cycling in tensile mode.  Stored energy is 
related to the ability of a viscoelastic material to recover following strain, similar to the 
energy in a spring.[8]  As can be observed in figure 2 and figure 3, the stored energy of 
modified samples in either solvent system did not show a significant change from that of 
control PU samples.  A significant change could be observed in each sample following 
cycling due to the plastic, non recoverable, changes to the PU samples.  Modified 
samples also showed similar energies and curves following each step of the cycling 
which suggests that the samples did not lose their durability during the chemical 
modification and should fatigue in a manner similar to that seen in grafts constructed 
from unmodified PU. 
 Because of the importance of sample compliance to success of an implanted 
vascular graft, this property was also measure prior to and following mechanical cycling.  
Significant changes were seen between rate of change of the measured compliance and 
the minimum measured compliance of the samples following fatigue cycling, however as 
was observed in the stored energy, the compliance was not observed to be different in 
modified samples suggesting that these samples would function as samples designed 
from unmodified PU.   
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 While this data has shown that there is no significant energy change or change in 
the compliance due to the surface modification, several outside factors also influence 
fatigue.  All samples were measured at physiological temperature, 37oC, these samples 
were fatigued in a non wetted condition.  Since part of the fatigue concerns have been 
associated with calcification[25, 28], it is unknown if the chemical modification will 
affect the absorption characteristics of the polymer, but it is reasonable to assume that 
since the modification completed on surface amines that the net ionic properties of the 
surface could be changed to affect long term durability.  It is also important to note that 
these samples were analyzed in tensile mode while mechanical testing is normal designed 
to test the sample using a method which closely simulates that of natural use.  Because 
samples were obtained as extruded films rather than in liquid solvent or molded in tube 
form which could be tested through pulsed forced flow, it was decided that stretching 
along the axis would be most representative of the forces.  Finally it is also important to 
note that the force used for cycling was not physiological, but increased to do plastic 
deformations onto the samples in hopes that this would help to show what would occur in 
long term use rather than measuring under physiological conditions which would only 
demonstrate short term fatigue effects.  However it should be noted for control PU and 
PU modified in both solvents all physiological loads, which is normally tested between 5 
and 25 kPa,[10, 24] would be on the elastic portion of the their pre-fatigue stress strain 
curve (figure 2) and as such would have negligible energy loss.
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Conclusions 
 Polyurethanes have been used in the design of vascular grafts because their 
mechanical properties, specifically the elastic modulus and the compliance, are on the 
same order of magnitude as vascular tissues.  While methods have been designed to 
create small diameter grafts with the correct mechanical responses and flow patterns, 
there is a need to modify the surface to prevent fibrous build up which can lead to 
occlusion.  This study has demonstrated that the modulus of the modified surfaces, while 
reduced is still sufficient for use in graft design.  This study has also shown that the long 
term durability following mechanical cycling is not affected by the chemical 
modification.  
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Figure 1. Mechanical analysis of Polyurethane Samples. 
 
Initial modulus of control and modified polyurethanes as a function of solvent system 
used during modification.  Modulus was determined in tension with a constant strain rate 
of 0.5 N / min at 37oC.  Sample modulus was normalized to the average modulus of 
control unmodified Chronoflex AR.  Average modulus of control, 8.695 ± 0.319 MPa.  
Error bars represent one standard deviation. 
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Figure 2 Stress Strain Curves as a Function of Solvent 
 
Stress-strain curves were generated for control PU and modified PU samples prior to and 
following fatigue applications. Measurements were taken at a strain rate of 5% strain per 
minute until 25% strain was reached.  Top curve in each panel taken prior to fatigue 
testing, middle curve in each panel taken after 500 cycles from 1 to 12.5% strain, bottom 
curve in each panel take following 500 cycles of 1 to 25%.
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Initial Post Fatigue 1 
Post Fatigue 
2 
  Stored 
Energy 
MPa 
Standard 
Deviation
Stored 
Energy 
MPa 
Standard 
Deviation
Stored 
Energy 
MPa 
Standard 
Deviation 
Control 0.404 0.030 0.325 0.022 0.237 0.024 
Hexanes 0.397 0.031 0.322 0.027 0.228 0.026 
Hexanes 
/ THF 0.382 0.007 0.318 0.005 0.235 0.010 
 
Figure 3: Stored Energy of Polyurethane Samples Prior to and Following Fatigue 
Cycling 
 
PU control and modified samples were measured to 25% strain at a 5% strain/min rate 
prior to and following fatigue cycling.  The stress-strain curves were numerically 
integrated to calculate the stored energy of the polymer sample.  No significant difference 
was seen in the stored energy between control PU and PU modified in either pure 
hexanes or 50/50 (v/v) mixture of hexanes and THF (p>0.15)
 84
0
20000
40000
60000
80000
100000
120000
0 0.5 1 1.5 2 2.5 3
Stress (MPa)
Co
m
pl
ia
nc
e 
(µ
m
²/N
)
0
50000
100000
150000
200000
250000
300000
0 0.5 1 1.5 2 2.5 3
Stress (MPa)
C
om
pl
ia
nc
e 
(µ
m
²/N
)
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
0 0.5 1 1.5 2 2.5
Stress (MPa)
Co
m
pl
ia
nc
e 
(µ
m
²/N
)
 
 
Figure 4: Compliance Curves for Control PU 
 
Compliance curves for control Chronoflex AR PU prior to and following fatigue testing. 
Measurements were taken at a strain rate of 5% strain per minute until 25% strain was 
reached.  Top panel taken prior to fatigue testing, middle panel taken after 500 cycles 
from 1 to 12.5% strain, bottom panel take following 500 cycles of 1 to 25%.  At least 5 
samples composed of test strips from at least 2 solvent cast films. 
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Figure 5 Compliance Curves for PU Modified in Pure Hexanes  
 
Compliance curves for PU modified in pure hexanes solvent prior to and following 
fatigue testing. Measurements were taken at a strain rate of 5% strain per minute until 
25% strain was reached.  Top panel taken prior to fatigue testing, middle panel taken 
after 500 cycles from 1 to 12.5% strain, bottom panel take following 500 cycles of 1 to 
25%.  Data presented is composed of at least 5 samples composed of test strips from at 
least 2 synthesis.
 86
0
20000
40000
60000
80000
100000
120000
0 0.5 1 1.5 2 2.5 3
Stress (MPa)
Co
m
pl
ia
nc
e 
(µ
m
²/N
)
0
50000
100000
150000
200000
250000
300000
0 0.5 1 1.5 2 2.5 3
Stress (MPa)
Co
m
pl
ia
nc
e 
(µ
m
²/N
)
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
0 0.5 1 1.5 2 2.5
Stress (MPa)
Co
m
pl
ia
nc
e 
(µ
m
²/N
)
 
 
Figure 6: Compliance Curves for PU Modified in a 50/50 (v/v) Mixture of Hexanes 
and THF 
 
Compliance curves for PU modified in a 50/50 solvent mixture of hexanes and THF prior 
to and following fatigue testing. Measurements were taken at a strain rate of 5% strain 
per minute until 25% strain was reached.  Top panel taken prior to fatigue testing, middle 
panel taken after 500 cycles from 1 to 12.5% strain, bottom panel take following 500 
cycles of 1 to 25%.  Data presented is composed of at least 5 samples composed of test 
strips from at least 2 synthesis.
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Figure 7 Summary of Compliance Testing 
 
Slope and minimum reached of control Chronoflex AR PU and modified PU following 
fatigue testing.  First column is value with second column be the standard deviation of at 
least 5 samples composed of test strips from at least 2 synthesis. 
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Chapter 3 
Development of an Endothelial Cell Mimicking Vascular Surface  
by Co-immobilization of Thrombomodulin and EPCR 
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Abstract 
In the normal endothelium; thrombomodulin (TM) and endothelial protein C receptor 
(EPCR), are well-integrated to regulate the protein C (PC) anticoagulant pathway. Recent 
studies have demonstrated that surfaced coatings of TM are able to prevent some of the 
complications involved with fibrous clot formation on natural or synthetic surfaces.  
However, at a certain surface density, the TM activation process becomes substrate 
transport limiting, a process which EPCR overcomes in vivo by increasing the surface 
transport of PC to the endothelial cell surface. The central goal of this study is to examine 
the influence of co-immobilizing rEPCR with TM on a biomaterial surfaces has on the 
activation of PC.  TM and EPCR were immobilized on Ultrabind™ membranes,  a 
porous surface which covalently binds proteins often used in immuno-blotting and 
biological sensor development.  Membrane bound TM activated PC in increasing 
amounts until a surface density of 50-100 ngs was reached confirming previous data 
however coimmobilizations of TM and rEPCR were statistically indifferent from samples 
containing TM alone. 
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Introduction 
 Small diameter vascular grafts suffer from patency issues resulting from thrombi 
initiated occlusion.  Biomaterial induced thrombosis is a complex issue, which involves 
several different enzymatic processes and is also impacted by the flow dynamics and the 
interactions of the material surface with blood or serum.[1-3]  To better understand this 
process, it is necessary to review the systems involved in the mechanism of thrombosis, 
the methods that the body employs to maintain haemostasis and finally potential methods 
used to overcome thrombosis for artificial surfaces. 
 The primary mechanism of thrombosis, in vivo, is effected through the activation 
of the clotting cascade that relies on two separate  pathways, the intrinsic and extrinsic 
pathways, which finally converge to common final pathway.[4]   However on implants 
and biomaterial surfaces, the pathway is initiated by the adsorption of initiator proteins, 
prekallikrein, high molecular weight kininogen (HMWK) and Factor XII.[1, 2]  The 
autoactivation of Factor XII to  Factor XIIa is thought to begin the intrinsic clotting 
cascade, which in turn activates downstream targets, Factor XI and Factor IX.  The 
extrinsic clotting cascade is activated through the protein tissue factor (TF).  TF is a 
membrane bound protein found at the site of vascular injuries.  In this system, Factor VII 
is absorbed onto the cell surface where it is activated by TF to form a TF/VIIa 
complex.[5]  This complex and Factor IXa are both able to activate Factor X which is the 
beginning of the common pathway.  Factor Xa interacts with Factor Va, Ca2+, and 
phospholipids to form the prothrombinase complex which converts prothrombin to 
thrombin, the enzyme which polymerizes fibrinogen to fibrin, forming fibrous clots.[6]  
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 Also involved in clot formation are platelets.  Platelets are anuclear cells which 
circulate in the blood inertly until activated and are designed to give mechanical stability 
to the formed clot.  The activation of platelets can come through several different 
mechanisms, however most of these mechanisms are protein receptor regulated.[7]  
Platelets are able to be activated by extracellular matrix proteins such as collagen and 
blood proteins which attach to the sites of vascular injury including fibrinogen and von 
Willebrand Factor (vWF) allowing for attachment at the site of vascular injury.[7, 8]  Cell 
membrane proteins such as epinephrine, thromboxane and platelet activating factor can 
also activate platelets and proceed through a mechanism where these proteins are 
upregulated upon vascular cell injury or which are normally only found in sub-
endothelial cells.[9]  Upon activation, platelets elongate and release their granules which 
contain ADP which is able to activate more platelets as well as stimulating their 
aggregation.[10]  Platelets are also able to be activated through thrombin allowing for a 
connection to the intrinsic pathway.[7]  This process is further linked by the platelet 
acting as a site for Factor XIa and Factor IXa which then proceeds to the common 
pathway and further thrombin generation and fibrin polymerization.[4]  
 Thrombin is a key enzyme that links these two processes, creating the fibrous clot 
through the polymerization of fibrin, activating platelets and forming fibrin networks 
which stabilize platelet clots.[10-12]  Thrombin is the active form of the zymogen 
prothrombin formed by two polypeptide chain linked through a disulfide bond.  
Thrombin exists in two forms, a fast form and a slow form which regulated through its 
binding with sodium.  In the fast, more enzymatically active form, Na+ ions are bound to 
a region with a high concentration of negatively charged amino acids near the C-terminus 
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of the enzyme.[13, 14]  The binding of sodium creates a three dimensional change in the 
formation of the active site of the thrombin enzyme.  These changes have been shown to 
change the substrate binding kinetics (Km), the rate of reaction (Kcat) and the enzymes 
ability to react in the anticoagulant protein C pathway.[12] 
 Thrombin is very interesting within the coagulation cascade as it both up regulates 
and down regulates its own concentration within the clotting cascade.  In the intrinsic 
pathway, thrombin activates Factor VIII which forms a complex with Factor IXa.  The 
Factor VIIIa / Factor IXa complex has been shown through 105 – 106 more active than 
Factor IXa alone and it is through this formed complex that greater than 90% of the 
Factor X used in a clotting reaction is activated.[15]  Thrombin also activates Factor V, 
which then forms a complex with Factor Xa that results in thrombin formation.  This 
complex has been shown to be 300,000 times more active than Factor Xa alone.[16, 17]  
The production of Factor Xa in the absence of Factor VIIIa and the production of 
thrombin in the absence of Factor Va is often considered a part of the initiation and the 
priming concentration of thrombin is necessary for an actual clotting event.[18]  
Thrombin also influences the down regulation of its concentration through the activation 
of the anticoagulant Protein C, one of the critical molecules to the regulation of 
haemostasis.[19] 
 Thrombosis on the surface of blood contacting biomaterials is a complex process 
that begins with the adsorption of serum proteins whose composition and rate of 
adsorption are partly dictated by surface characteristics.[1, 20, 21]  The initial adsorption 
of proteins is based upon the concentration of the proteins in the blood, as a result initial 
adsorption has the greatest concentration of IgG, fibrinogen and albumin.[20]  Adsorbed 
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albumin has been shown to passivate a surface to thrombosis, however adsorbed IgG has 
been shown to activate the complement system, which regulates inflammation.  
Adsorption of fibrinogen onto an artificial surface induces a conformation change which 
exposes receptors for platelet binding.[22]  Over time, high concentration but low 
molecular weight plasma proteins such as fibrinogen are exchanged for higher mass 
proteins such HWMK in what is known as the Vroman Effect.[20, 23]  As HWMK is 
able to activate the intrinsic clotting cascade, it is able to activate and recruit platelets to 
the fibrinogen remaining on the surface as well as form the fibrous network to stabilize 
the thrombus.  Platelet adsorption onto biomaterial surface has been shown to be shear 
rate dependant.[24]  At very low and high shear rates implanted surfaces have been 
shown to have low platelet adsorbance, however at intermediate flow rates platelet 
adsorbed at a high rate onto the biomaterials surface.[25, 26]  Platelet adsorption has also 
been shown to be dependant on different adsorbed proteins based upon the wall shear rate 
of the flow.[8]  At low and medium flow, in vitro tests have shown platelet adhesion to 
be fibrinogen dependant where as at higher shear rates, the adsorption is mediated by 
vWF which can also be absorbed through the Vrooman effect.[8] 
 The body and specifically the vascular endothelium provide several methods of 
regulating the different methods of thrombosis.[9]  The first method of regulation is the 
vascular cell membrane which is able to inhibit the nonspecific adsorption of serum 
proteins, inhibiting fibrinogen, HWMK and vWF adsorption which causes biomaterial 
thrombosis.  This phenomena is attributed to the chemical composition of the exposed 
membrane and the net negative charge of the membrane.[27] 
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 The second method used by the endothelium to regulate clot formation is through 
the use of soluble molecules such as prostacyclin and nitric oxide which inhibit platelet 
activation.  Prostacyclin is lipid molecule produced in endothelial cells from the reaction 
of membrane phospholipids with cyclooxygenase-2 (COX-2) and prostacyclin 
synthetase.[9, 28]  Once released from the cell, prostacyclin has two roles, when released 
into the smooth muscle of the vessel, the molecule causes vasorelaxation and when 
released into the blood reacts with platelets increasing the cAMP concentration which 
leads to decreased activation and aggregation.[29, 30]  Nitric oxide (NO) is also 
synthesized in the cell and acts in a very similar manner to prostacyclin.  NO is produced 
through the reaction of arginine and nitric oxide synthase.  Once released, NO like 
prostacyclin reacts with platelets but produces cGMP, having a similar decrease in 
platelet activation and aggregation.[9, 31]  
 The final method of regulation of haemostasis by the vascular endothelium is 
through many membrane bound proteins and molecules including heparin and 
thrombomodulin, both of which inhibit thrombin formation and propagation.  Heparin is 
a proteoglycan found on both the surface of the basement membrane of the sub-
endothelial matrix and on the endothelial cell membrane.[9, 32]  Heparin, both membrane 
bound and excreted, is able to bind a circulated serpin, antithrombin III, producing a 
conformation change in the antithrombin III which increases the activity of the molecule 
to bind and inactivate thrombin and Factor Xa more than 100 fold.[33] 
 Thrombomodulin (TM) is a 60 kDa transmembrane glycoprotein which binds 
thrombin in a 1:1 ratio and acts as a cofactor for the activation of the anticoagulant 
Protein C.[34]  TM is found on all vascular endothelial cells but its concentration is 
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variable with the largest surface density in capillaries.[35]  TM binds thrombin in its fifth 
and sixth epithelial growth factor like domains, when bound the thrombin is unable to 
catalyze the formation of fibrin from fibrinogen, but also activates Protein C at a rate 
greater than 1000 faster than unbound thrombin.[12, 19, 36]  Though the binding of 
thrombin is reversible and very fast with a half life of approximately three seconds[37], 
the binding of thrombin to TM has been shown to be make the thrombin more susceptible 
to antithrombin inactivation by greater than 20 times due to a chondroitin sulfate branch 
near the bound thrombin.[38]  In addition, any active thrombin released by TM is in the 
slow conformational form.  The importance of TM is evident in the study where a 30 fold 
loss of TM was seen in the first 3 days after implantation venous vascular graft associated 
with early graft failure normally from thrombus formation.[39] 
 Protein C (PC) is a 62 kDa zymogen which circulates through the blood at a 
cocncentration of 0.0645 µM, significantly less than the 2.4 µM of antithrombin III.[12]  
PC once activated by the thrombin /TM complex reacts through competitive inhibition 
with Factor Va and Factor VIIIa.[40]  The inhibition of these molecules inactivates the 
Factor VIIIa / Factor IXa complex used to produce Factor Xa and the Factor Xa / Factor 
Va complex used to activate thrombin. 
 Though the concentration of PC is lower than that of antithrombin III, activated 
Protein C (aPC) plays a vital role in the regulation of haemostasis, both during clotting 
events and under normal flow.[35, 40]  In the capillaries, the concentration of TM is large 
enough to bind all activated thrombin which passes through the capillary bed with the 
production of aPC in the capillaries able to prevent occlusion from fibrous 
polymerization.[41]  In larger blood vessels, aPC is released into the boundary layer near 
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to the vascular wall.  Due to its half life of approximately 15 minutes, the aPC unlike the 
antithrombin which must remain bound to heparin to remain active is able to be released 
into the blood and inactivate thrombin formation near or on the surface.[40] 
 The rate of activation by PC by TM can be increased by its co-localization with 
endothelial protein C receptor (EPCR).  Values for the increase vary between 5x and 20x 
increase in the rate of reaction, however blocking the active site of EPCR in baboon 
arteries in vivo showed an 86% decrease in the production of aPC.[42]  The 
concentration of EPCR is variable in the vascular system with high concentrations in 
large arteries and the umbilical cord with no EPCR found on endothelial cells of 
capillaries and reaching a  ratio of approximately 7:1 for HUVEC cells.[43]  The areas of 
largest concentration of EPCR are areas containing a 100 time increase in the blood to 
TM ratio over that of capillaries suggesting that EPCR is most necessary where PC in the 
blood might need to be transported to the TM protein for activation.[44]  It is through this 
mechanism that EPCR functions.  Studies showed that EPCR has an effective binding 
constant of 29 nM towards PC, in comparison to 266 nM when EPCR or Mg2+, a 
necessary ion for function, is blocked.[45]  Crystallography studies further confirmed the 
mechanism by showing that when bound to EPCR, the cleavage site for activation is 
presented outward for reaction with the TM/ thrombin complex.[35, 46]  In addition 
studies attempting to incubate EPCR with TM were not able to isolate any EPCR / TM 
complexes suggesting that the two proteins do not interact physically.[45]  This 
mechanism does have a limitation as EPCR shows the same binding efficiency for both 
PC and aPC.  As a result of this, aPC can remain on the surface bound to EPCR and in 
this surface bound state shows less activity as an anticoagulant.[45]  aPC bound to EPCR 
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has also been shown to be more stable and the overall efficiency of the TM/ thrombin 
activation system is not inhibited as it is when EPCR is fully blocked by antibodies.[47] 
 Due to the thrombogenic nature of biomaterial implants, several different method 
used by the endothelium and nature have been incorporated into surfaces in an attempt to 
reduce clot formation.  To reduce the adsorption of nonspecific proteins materials have 
been coated with molecules similar to or found in the cell membrane.  Often 
phospholipids are used to create the coating[48, 49] which also allow for the anchoring of 
cell membrane proteins with trans-membrane domains to attached in a manner which 
orients them correctly and maintains their proper three dimensional structure.[49]  
Coatings of polymers, such as polyethylene oxide (PEO), polyethylene glycol (PEG), 
have also been designed to reduce the hydrophobicity of the surface of the material.[50]  
Other techniques to passivate the surface have been developed by attaching molecules 
from the blood.  These molecules, which include albumin[51] and cholesterol,[52] create 
a surface coating which the body should not recognize as foreign. 
 Several surface modifications have been designed to control thrombin production 
on the surface of the material.  These modifications range from the use of direct thrombin 
binding peptides to venoms to bioactive molecules found on the endothelial 
membrane.[53]  Direct thrombin peptides are surface coatings which bind 1:1 with a 
thrombin molecule and block the active site of thrombin to prevent the formation of fibrin 
to fibrinogen.  The advantage of this coating is that the peptides can remain stable for a 
longer period of time as compared to immobilized proteins because these peptides do not 
have a complex three dimensional structure.  Hirudin is a specific example of a direct 
thrombin inhibiting peptide which has be isolated from the venom of leeches.[12]  This 
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peptide has the ability to irreversibly inactivate thrombin and also has the ability to bind 
to and inactivate thrombin which has already bound to fibrin.[54]  A limitation of hirudin 
and other direct thrombin inhibitors is the 1:1 ratio for inhibition and that these peptides 
do not deactivate the clotting cascade which continues to activate thrombin. 
 The immobilization of heparin has been investigated as a method of decreasing 
thrombosis on blood contacting devices for several decades and has been used as a 
coating for circulating devices, stents and vascular grafts.  Heparin has been 
experimented with on several different materials including polyethylene[55], 
polyester[56], polyurethanes[57], expanded polytetrafluoroethylene[58] and 
collagens[59] covalently bound either directly to the surface or through a chain extension 
from the surface.  In these cases, heparin immobilized surface have shown a lengthening 
of the clotting time.  The ability of the heparin to inhibit the clotting mechanism has been 
shown to depend on the molecular weight of the heparins immobilized, the orientation of 
the heparin on the surface and whether a spacer arm was used to extend the heparin 
molecule off the material surface.[50]  Generally, heparins immobilized through their 
reducing ends and extended from the surface by a spacing polymer are more active due to 
the better exposure of the active sites.[60, 61]  Despite the immobilization techniques, the 
activity of heparin is significantly decreased by its immobilization onto the material 
surface, estimated to retain only 1% of its activity.[50]  This loss of activity is partially 
expected as antithrombin III is only active when bound to thrombin and the complex is 
unable to inhibit thrombin that is already reacting with fibrinogen, as biomaterial surface 
bound thrombin would be.  There is debate if the reduction of clotting is due to the 
formation of the heparin / antithrombin III complex and the thrombin inhibition 
 101
mechanism, instead suggesting that the heparin coating binds to other blood proteins with 
heparin binding sites creating a layer of specific blood proteins which acts in a manner 
similar to an albumin coating.[62]  Despite the mechanism, heparin coated grafts have 
shown slightly better patency rates in one and two year trials,[63, 64] though in studies 
the ability to inhibit thrombin formation has been no different that control samples.[65] 
 TM has also been covalently immobilized onto several different surfaces 
including expanded polytetrafluoroethylene[66], polyurethane[67], polyacrylic acid[68], 
celluslose[69], agarose[70], nitinol[71] and glass[72].  Coatings of TM range in 
concentration from 1.5 µg/cm2 [71] to physiological levels found on the surface of the 
endothelial cell of approximately 10 ng/cm2 [49] during which the activity of the coating 
was shown to be proportional to the concentration of TM until the rate reached a 
maximum at approximately 8x physiological levels.[49]  Most samples have been tested 
to show the ability of the surface to activate PC in the presence of thrombin under static 
or flow conditions, however TM coated surfaces have also shown the ability to decrease 
platelet activation and adhesion in vitro.[71, 73]  Clotting experiments on TM 
immobilized showed a significant extension to clot formation when compared to either 
control surfaces or surface coated with albumin.  During these experiments, the activity 
of surface immobilized TM was compared to soluble TM which showed surface activity 
of 10-33% that of soluble TM.[67, 68]  While this loss of activity is significant, it is less 
activity loss than the 1% of soluble activity seen with heparin coated surfaces.  The 
activity of TM is a concern as immobilized proteins are susceptible to cleavage and can 
denature over time.  Although long term data is not available, activity tests have been 
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conducted for 90 days, showing an initial activity loss during the first 15 days at which 
point a stable activity existed for the duration of the study.[49] 
  Recently, surfaces have been designed to better mimic the endothelium by 
combining several of the methods of regulating hemostasis found on the membrane.  
These surfaces combine the effects of phospholipid membrane with TM[49], a membrane 
and TM and heparin,[74] and TM and heparin and nitric oxide production[31].  The 
methods combine methods used to control thrombin concentration, prevent non-specific 
protein adsorption and prevent platelet adhesion and activation.  The addition of lipid 
layer was designed to serve a second purpose ensuring the proper alignment of the TM on 
the materials surface increasing the activity.[49]  The addition of heparin to TM surfaces 
would seem to create a competition for available thrombin to activate the TM / PC 
reaction, however in vivo thrombin attached to TM is more susceptible to anti-thrombin 
inactivation and the addition of the heparin to the surface ensures all released thrombin is 
inactivated.[74]  Surfaces releasing NO have been prepared in two manners, either 
through time release loading[31] or through the immobilization of copper compounds 
which react with nitrosothiols which circulate in the blood.[75]  These surfaces have 
shown the ability to inhibit platelet adhesion and activation and also the ability to activate 
PC, however clotting time data or the interaction of these surfaces with blood has not 
been published.[31] 
 The research into the creation of vascular biomimetic surfaces has demonstrated 
that the immobilization of endothelial cell groups such as TM and heparin onto a polymer 
surface are able to significantly inhibit clotting effects when contacted with blood.  Of 
these molecules, TM shows the most promise for immobilization onto implantable 
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surfaces due to its demonstrated ability to prevent hyperplasia on polyester grafts and its 
ability to completely arrest thrombin formation when expressed at arterial concentrations 
on venous grafts.  TM’s ability to completely prevent the formation of thrombin has not 
been able to be transferred from natural endothelial cell covered venous grafts to polymer 
grafts as the polymer implants do not contain a cell membrane which aids in the 
inhibition of clotting.  While other studies have tried to incorporate a phospholipid layer 
on the material surface, they have found that the TM containing surface becomes PC 
transport limited.  
 This research proposes the covalent co-immobilization of TM with its 
endothelium membrane cofactor EPCR.  In this study, we will produce a recombinant 
protein containing the cytosolic domains of the EPCR protein in Pichia Pastoris yeast and 
describe the purification of this protein via a histidine tag incorporated in the recombinant 
sequence.  We will demonstrate that the EPCR produced will bind PC and does not 
inhibit the activation of PC by the TM / Thr complex.  We hypothesize that by co-
immobilizing EPCR with TM on a solid support the ability of the immobilized TM to 
activate PC will be increased.
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Methods 
Construction of an EPCR expression plasmid for expression and secretion in P. 
pastoris 
Construction and expression of EPCR-LL-His6 [76] 
In order to construct the recombinant EPCR–LL-Xa-His protein expression 
plasmid pPICzA-EPCR-Lys2-Xa-His6 (Figure 1B) primer pairs were designed on the 
base of the human EPCR sequence (corresponding to the residues 1–194, mature protein 
numbering) and inserting the coding sequences for two Lys residues, a Factor Xa 
cleavage site and six His residues at the C-terminal of EPCR sequence. The inserts were 
prepared via PCR. and the respective sequences of the forward and reverse primers 
designed to construct pPICZαA- EPCR-His6 were:   
forward: 5- ATCTCGAGAAAAGATTTTGTAGCCAAGACGCCTC-3 
reverse: 5- 
TAGCGGCCGCTTAGTGATGGTGATGGTGATGTCTCCCTTCAATCTTCTTCGA
AGTGTAGGAGCG-3 
The bold underlined nucleotide bases indicate restriction-enzyme digestion-sites for Xho I 
and Not I. After amplification, the PCR product was digested by Xho I and Not I for at 
least 3h at 37 oC and then directionally ligated with pPICZA vector (Invitrogen) that 
was previously digested with both enzymes. The ligated plasmid was transformed into 
competent cells of E. coli strain TOPO 10 (Invitrogen) and then a positive clone was 
selected. The sequence of purified plasmid from TOPO 10 was confirmed by sequencing 
in order to verify that the ligations and the His-tagged EPCR insert were correctly in-
frame. About 5 g of purified plasmid that was previously digested with Pme I and 
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transformed into X-33 P. pastoris competent cells to express rEPCR-LL-Xa-His. The 
resulting clone was designated as X33-EPCR-LL-His. The expression of the EPCR-LL-
Xa-His was performed according the procedure described above for the expression of 
rEPCR.  
 
Purification of rEPCR-LL-Xa-His using Ni2+-IMAC column 
The tagged rEPCR was desalted using Econo-Pac 10DG desalting column (Bio-
Rad) and purified in a single step by metal-chelating affinity chromatography. The Ni2+-
IMAC purification (from 12 mL medium using 1 mL resin) procedure was carried out at 
4 oC according to the manufacturer’s instructions and rEPCR-LL-Xa-His protein was first 
eluted with 1 M imidazole, pH 7.9 and then desalted and concentrated using Amicon 
Ultra-4 Centrifugal Filter Unit with Ultracel-30 membrane (Millipore).  The final proteins 
were stored in PBS, pH 7.2. 
 
Evaluation of EPCR and hPC binding on surface immobilized rEPCR   
Purified rEPCR1LL-His protein was spotted onto dry UltrabindTM membranes, as 
separate experiments. 1 l of protein solution was applied per spot. Protein 
concentrations ranged from 0.0625 to 0.5 mg/ml in PBS buffer (10 mM phosphate 
dibasic, 25 mM NaCl, pH 7.2).  The spots were allowed to air dry and then the uncoupled 
reactive sites on the membranes were blocked with 1M ethanolamine, pH 9.2 solution for 
3 h at room temperature. The membranes were then separated into three sets.  The first  
set was equilibrated with a 5 g/ml of hPC solution in PBS, for 3 h at room temperature. 
Membranes were washed copiously with PBS and incubated with 1:1000th diluted HRP-
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conjugated rabbit anti-hPC antibody for 3 h at room temperature. The second set was 
incubated with a 1:1000 dilution of anti-EPCR polyclonal antibody.  Following washing 
with copious amounts of PBS, the membranes were incubated with a 1:1000 diluted HRP 
conjugated anti-rabbit antibody grown in goat.  The third set of samples were incubated 
with a 5 g/ml monoclonal antibody to EPCR designated RCR-2. Following washing 
with copious amounts of PBS, the membranes were incubated with a 1:1000 diluted HRP 
conjugated anti-rat antibody grown in rabbit. At the end of the incubation, membranes 
were washed and bound complex was detected via chemiluminiscent detection.  
 
Solution Phase Protein C Activation Assays 
 Protein solutions of recombinant EPCR-his, human thrombomodulin (TM, 
American Diagnostica Inc., Stamford, CT), human thrombin (Thr, American Diagnostica 
Inc., Stamford, CT), human Protein C (hPC, Enzyme Research Labs, South Bend, IN), 
human activated Protein C (aPC, Enzyme Research Labs, South Bend, IN),  were 
prepared in reaction buffer composed of 0.1 M NaCl (Sigma Aldrich, St. Louis, MO), 
0.003 M CaCl2 (Sigma Aldrich, St. Louis, MO), 0.0006 M MgCl2 (Sigma Aldrich, St. 
Louis, MO), 0.02 M Tris-HCl (Fisher Scientific, Pittsburgh, PA), 0.1 mg/ mL Bovine 
Serum Albumin (BSA, Sigma Aldrich, St. Louis, MO) and the pH adjusted to 7.5.  25 µl 
of a 0.36 mg / ml EPCR-his was incubated for 15 minutes with 25 µl of a 0.1 mg / ml 
hPC solution in a sterile 96 well cell culture plate (Fisher Scientific, Pittsburgh, PA)  
Following incubation, 25 µl of a 0.006 mg/ml TM solution was added to the reaction 
mixture.  25 µl 0.06 µg / ml Thr followed immediately by the addition of Spectrozyme 
aPC (American Diagnostica Inc., Stamford, CT)) to a final concentration of 0.0004 M.  
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The reaction was incubated at 37 oC with the absorbance at 405 nm-1 taken after 0, 5, 10, 
15, 20, 30, 45, 60, 75, 90 and 105 minutes using a Beckman Coulter AD 340 UV / Vis 
microplate reader.  Samples were preformed in triplicate and for samples without either 
EPCR or TM, the solution was replaced 0.08 mg / ml BSA solution.  The concentration 
of Protein C activated was calculated using an aPC in reaction buffer calibration curve on 
the same cell culture plate. 
 
Solid Phase Sample Preparation 
 Samples were prepared on 5 mm diameter punches of Ultrabind membrane made 
with a standard biopsy punch.  Samples were created with varying concentrations of TM 
alone, TM and EPCR-his, EPCR-his alone, and TM and RCR2 – EPCR-his.  EPCR 
containing samples were spotted in a 7:1 EPCR:TM concentration similar to that seen in 
vivo.  Samples were spotted as described above in 25 µl drops in a 96 well cell culture 
plate and allowed bind for 2 hours followed by blocking with ethanol amine as described 
above for 1 hour.  RCR-2 was immobilized at a molar ratio of 3.5:1 to TM to maintain 
the molar ratio of EPCR as each RCR-2 antibody can bind two EPCR molecules.  
Following blocking, sample containing were RCR2 were incubated for 5 hours with a 
10x excess solution of EPCR-his, washed and cross-linked for 2 hours with 2% 
gluteraldehyde.  Solid state samples were created at TM concentration of 0, 5 ngs/cm2 (70 
fmol/cm2), 10 ngs/cm2 (140 fmol/cm2), 50 ngs/cm2 (700 fmol/cm2), 100 ngs/cm2 (1400 
fmol/cm2) and 200 ngs/cm2 (2800 fmol/cm2).  All samples were washed and stored at 4 
oC in reaction buffer.  
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Solid Phase Protein C Activation Assays 
 Samples prepared previously were washed in 50 µl fresh reaction buffer prior to 
reaction.  Samples were incubated for 30 minutes at 37 oC with 50 µl of a 5 units / ml Thr 
solution with mixing.  Following incubation, the thrombin solution was removed but the 
samples not washed.  50 µl of a 0.025 mg / ml hPC solution was added to each sample 
and reacted at 37 oC with mixing for 1.5 hours.  The reaction was ended by the addition 
of 10 µl of anti-thrombin III (American Diagnostica Inc., Stamford, CT) to a final 
concentration of 6 units / ml.  Following 15 minutes of reaction of anti-thrombin with 
thrombin from the reaction, the solution was pipetted from the solid samples to new 96 
well plate.  To each solution sample, 40 µl of Spectrozyme aPC solution was added to a 
final concentration of 0.004 M.    Solution samples were incubated at 37oC analyzed 405 
nm-1.
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Results 
Expression and Purification of rEPCR in P. pastoris. 
 In order to confirm the expression of rEPCR by P. pastoris, samples of yeast 
culture supernatants were electrophoresed and electroblotted using a antibodies specific 
for EPCR.. The expression level of rEPCR was estimated by western blotting to be about 
20 mg/L of cell medium. The expressed rEPCR was heterogeneous, perhapsdue to the 
glycosylation by the enzymatic machinery present in yeast, with three distinct protein 
bands which cross reacted with anti-EPCR polyclonal antibody (the first upper strong 
band, middle band and the third, weak band).  
 rEPCR-LL-Xa-His was purified from yeast culture medium (Figure 1B) to 
homogeneity in one step using metal-chelating affinity chromatography using Ni2+-
IMAC column followed by ultrafiltration.  The purity of rEPCR-LL-Xa-His was 
confirmed by SDS-PAGE in which proteins in the gel were first visualized by Coomassie 
Brilliant Blue followed by silver staining (Figure 1C).  The purified protein appeared as a 
~40 kDa polypeptide on SDS-PAGE, similar to rEPCR (without His tag) 
immunoprecipitated from HUVEC and EPCR-positive E-7 cells.[45]  The expression 
level of rEPCR-LL-Xa-His was estimated to be ~6 mg per L of yeast culture medium.  
 
Solution Phase Testing 
The ability of TM to catalyze the activation of PC incubated with or in the absence of 
rEPCR was determined in solution.  This experiment was designed to ascertain that 
rEPCR when incubated with hPC in solution would not impact the rate of activation of 
hPC by TM in the presence of thrombin.  For samples lacking EPCR, a similar 
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concentration of BSA was incubated with the hPC.  This experiment was also conducted 
in the absence of TM and in the absence of both rEPCR and TM to establish that rEPCR 
did not have any catalytic activity, and that the activation of hPC was not catalyzed by 
thrombin alone which is known to occur in vivo but a significantly slower rate. The 
influence of rEPCR in solution on Protein C activation is presented in Figure 3. The 
presence of rEPCR in solution did not impact the PC activation by the TR:TM complex.  
Solution phase analysis also showed that there was no activation of hPC in the absence of 
TM. 
 
Dot Blot Analysis 
Purified rEPCR was spotted on dry UltrabindTM membranes, and these studies were 
performed such that identical sets of replicate applications of immobilized rEPCR could 
be subjected to an ordinary sandwich ELISA to measure the immunosorptive capacity for 
hPC by surface immobilized EPCR or antigenicity and functionality could be confirmed 
by dot-blot analyses by reacting these membranes with monoclonal and polyclonal 
antibodies with documented reactivities to native EPCR.  UltrabindTM membranes 
provide an activated surface for the covalent attachment of proteins and diffuse-
refelectance-densitometry provides a precise detection of chromophoric signals and has 
been reported elsewhere.[77]  The signal to noise ratio was greater than 100/1. A 2 to 4% 
variance in ELISA signals was found between replicate applications within a sheet. When 
hPC was not included in the ELISA procedures, essentially no signal was generated (data 
not shown).  
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UltrabindTM surfaces with immobilized rEPCR.  
UltrabindTM membranes with indicated amounts of TM, rEPCR and rEPCR/TM were 
prepared as detailed earlier and the activation of PC by surface immobilized TM, rEPCR 
and rEPCR/TM was evaluated and presented in Figure 4. Controls correspond to 
membranes with no immobilized protein, however blocked and treated similarly as the 
test surfaces. Solid state samples were created at TM concentration of 0, 5 ngs/cm2 (70 
fmol/cm2), 10 ngs/cm2 (140 fmol/cm2), 50 ngs/cm2 (700 fmol/cm2), 100 ngs/cm2 (1400 
fmol/cm2) and 200 ngs/cm2 (2800 fmol/cm2).  Samples containing EPCR were 
immobilized at a molar ratio of 7:1 to mimic that found in vivo.[43]  The increase in the 
amount of APC released correlated with increasing amounts of TM on the membrane 
until a maximum was reached between a surface concentration of 50 ngs of TM/cm2 (700 
fmol/cm2) and 100 ngs/cm2.  Co-immobilizations of EPCR and TM, albeit randomly, also 
yielded higher amounts of APC with increasing ratios of EPCR/TM until a maximum 
was reached at the same concentration of TM.  While the concentration of APC was 
statistically different at the different surface densities of TM until the concentration of 50 
ng/cm2 was reached, samples immobilized with and without rEPCR with corresponding 
concentrations of TM were statistically indifferent from each other. 
 
EPCR is functionally polar, in the sense that the hPC binding domain on the EPCR 
molecule resides on the –NH2 terminal. To achieve directional immobilization, in 
separate experiments, RCR-2, a Mab directed against EPCR and that binds EPCR via a 
domain close to the –COOH terminal was first co-immobilized with TM at indicated 
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concentration and ratios.[78]   RCR-2 was immobilized at a molar ratio of 3.5:1 to TM to 
maintain the molar ratio of EPCR as each RCR-2 antibody can bind two EPCR 
molecules.  Upon completion of the protein immobilization step, the residual active sites 
were blocked and membranes were exposed to rEPCR solutions, washed and the rEPCR 
bound to RCR-2 was crosslinked with glutraldehyde. The activation of PC on test 
surfaces with co-immobilized TM and RCR-2/EPCR were also evaluated and presented 
in Figure 4. While increased APC was noted at higher ratios, the differences were not 
statistically significant. 
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Discussion 
Thrombomodulin (TM) is a surface bound protein whose concentration and activity has 
been shown to be relevant to the success of implanted venous vascular grafts.[39]  In 
these studies veins implanted as arterial grafts showed a loss of functional TM which 
corresponded to a loss of patency due to thrombosis.  Reintroduction of TM to arterial 
levels through gene therapy showed an increase in patency but was not able to overcome 
hyperplasia formation due to compliance mismatch of venous tissue.  However these 
results suggest the importance of the TM / Protein C (PC) activation system to the 
regulation of thrombosis in potential vascular grafts.  In other studies, TM immobilization 
has been shown to inhibit the formation of hyperplasia, a fibrous occlusion found on 
grafts with a compliance mismatch leading in to areas of improper blood flow, often 
found on vascular grafts constructed polyester.[79]  Because of this importance, TM has 
been immobilized onto the several different biomaterials to test the ability of the 
immobilized protein to activate PC in both static and flow studies.  In these studies, the 
activation of PC has been shown to be proportional to the surface concentration of TM 
until it reaches a concentration corresponding to approximately 8 times the native arterial 
concentration.[47]  Native arteries however contain a surface bound cofactor to TM, 
Endothelial Protein C Receptor (EPCR) which shows a strong affinity for the PC 
increasing the activity of the TM mediated PC activation.[45] 
 Recombinant EPCR constructs were prepared in Picia Pastoris and designed with 
a secretion signal and a poly-histidine tail within the construct to create a one step 
purification process.  The construct encoded the cytosolic portion of the transmembrane 
EPCR protein and was recognized by both polyclonal and monoclonal antibodies against 
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native EPCR as well as showing an activity towards the binding of HRP conjugated PC 
(figure 2).  Pichia Pastoris was chosen to produce the recombinant EPCR due to its ability 
to produce recombinant proteins at higher fermentation rates than mammalian or plant 
cultured cells while enabling for secreted proteins with folding more similar to eukaryotic 
cells than those produced by bacteria due to is ability to correctly glycosylate asparagine 
amides and serine and threonine hydroxyl groups.[80]  It is important to note that Pichia 
glycosylations contain different sugars, branching and length than proteins produced by 
mammalian cells which can produce an immune response, however Pichia has been 
shown to produce shorter polysaccharides than other yeasts, such as Saccharomyces 
cervisiae.[81]  More recently certain Pichia clones have been engineered to produce fully 
human glycosylated proteins which could be cloned into prior to in vivo testing.[82] 
 
The binding of the EPCR by the monoclonal antibody designated RCR-2 served two 
purposes, first to identify the recombinant protein and secondly to create a method for 
proper oriented immobilization of EPCR.  RCR-2 has been shown previously to identify 
a region near the transmembrane domain on the cytosolic EPCR and not alter the PC 
binding affinity to EPCR while bound.[78]  By immobilizing RCR-2 onto a surface and 
then binding the EPCR through the antibody, it would ensure that EPCR would be 
extended from the surface in a manner mimicking the orientation from the cell membrane 
which should provide proper binding of PC.  
 
Solution phase experiments were conducted to verify that the rEPCR protein will not 
inhibit or interfere with the ability of TM to bind PC that had been bound to EPCR as 
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well as verify that EPCR had no catalytic activity to activate PC in the absence of TM 
and TR.  Upon analysis of these reactions it was determined that the incubation of PC 
with soluble EPCR did not affect the reaction rate of TM, figure 3.   In addition, EPCR 
with a BSA replacement for TM showed no activation.  These two results when 
combined confirm that EPCR does not catalytically activate the PC and does not create a 
conformational change in either the PC or TM to increase the activity, as is the case with 
other proteins involved with haemostasis such as the relationship between heparin and 
anti-thrombin III or thrombin and sodium.  Instead, this suggests that the activation 
increase is likely caused by an increase in the transport of PC to the surface and proper 
presentation of PC by EPCR to TM on the surface. 
      
Co-immobilizations were conducted using UltrabindTM, a preactivated membrane that 
enables the primary amines on proteins to react with the pendant aldehyde group on the 
membrane to yield covalent linkages via the formation of an amide bond, as a model 
surface.  UltrabindTM is an ideal surface for initial testing due to its large protein binding 
and retention rates (306 µg/cm2 when binding IgG with 89% retention following washes 
including detergent)[83] and because of these properties has been used in the initial 
phases of sensor development.[84]  The limitation of immobilizations on this surface is 
that co-immobilizations can only be effected via differential reactivities of proteins or 
concentration gradients. While rEPCR and TM were both immobilized onto the same 
UltrabindTM membrane, the random nature could not ensure proximal immobilizations so 
as to catalyze the PC activation was not achieved. As a result no statistical differences 
were noted between the amount of APC generated by surfaces displaying TM or 
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TM+rEPCR.  The orientation of EPCR did not affect the activation of PC on a randomly 
immobilized surface as there was no significant difference between samples containing 
TM and (TM+RCR2)+EPCR.  The model did allow us to study the effect of TM 
concentration on the activation of PC and determine the concentration at which the 
activation reaches steady state, which confirmed similar studies.[49] 
 
As the addition of the EPCR directly to the surface or via the RCR-2 showed no 
significant change, it must be deteremined why no increase was seen despite an expected 
5x – 20x increase in the activity.[85]  This lack of increase in activity could be due to the 
EPCR recombinant protein being inactive, the surface bound protein being inactive in the 
bound form or that the EPCR and TM are not immobilized on a scale to allow them to 
interact.  Because EPCR attached to the ultrabind membrane was able to bind PC in the 
absence of TM shown in figure 2, it does not follow that EPCR is inactive.  Also if there 
had been any loss in activity due to the method of EPCR binding to the surface, this 
should have been solved by first immobilizing the RCR-2 antibody onto the membrane 
followed by EPCR. 
 The mechanism by which EPCR acts upon the TM/PC is known to be related to 
the transport of PC to the endothelial surface from the blood with PC first binding to 
EPCR.  Crystallographic studies of Protein C bound to EPCR show that when bound 
Protein C is in presented in an orientation that allows it to be activated by the 
thrombomodulin-thrombin complex suggesting that Protein C is activated while still 
bound to EPCR.[46]  This mechanism has been further confirmed by incubating Protein 
C with and without soluble EPCR prior to activating in solution phase, both having the 
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same reaction rates.  Should this mechanism hold true, it would require that the EPCR 
and thrombomodulin be localized together on the surface.  On the cell membrane, Protein 
C bound to EPCR has been determined through fluorescence energy transfer to be at a 
height of approximately 94 Å and thrombin bound to thrombomodulin at approximately 
64 Å above the cell membrane.[86]  If these protein complexes were approximated as a 
sphere with the height as the diameter where the reaction sites are able move along the 
surface of the sphere this would require that EPCR and thrombomodulin be immobilized 
on a surface by a separation of less than 80 Å or 8 nm.  While the 7:1 EPCR to TM ratio 
should produce so EPCR within this therapeutic distance, it was not enough to create a 
significant change in the amount of aPC generated in static experiments over samples 
with TM alone. 
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Conclusions 
 
We have demonstrated a method for producing, purifying and characterizing recombinant 
human for EPCR from Pichia Pastoris yeast.  We have shown that these proteins can be 
immobilized on to surfaces and are active in their ability to bind PC.  We have further 
shown that our recombinant EPCR does not inhibit the activation of PC by the TM / 
thrombin complex.  Finally we have produced results which show that either an oriented 
or non-oriented state that EPCR must be colocalized within a specific 3D distance to TM 
to produce an increase in PC activation activity.
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Figure 1: Analysis of recombinant EPCR production and purification. 
Analysis of rEPCR produced as an excreted protein in Picia Pastoris and purification by 
Ni2+-IMAC column.  A) Western Blot of media containing excreted rEPCR protein prior 
to purification.  B) Commassie Blue stained SDS-Page electrophoresis gel for media 
containing rEPCR produced in Pichia Pastoris.  Lane 1 positive control, lane 2,4 negative 
control, lane 3,5 EPCR expressing cells.  C) Commassie Blue stained SDS-Page 
electrophoresis gel of rEPCR purification by Ni2+-IMAC column followed by 
ultrafiltration.
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Figure 2:   Characterization of EPCR. 
Purified rEPCR protein was spotted onto dry UltrabindTM membranes, as separate 
experiments. 1 l of protein solution was applied per spot. Protein concentrations ranged 
from 0.0625 to 0.5 mg/ml in PBS buffer (10 mM phosphate dibasic, 25 mM NaCl, pH 
7.2).  The spots were allowed to air dry and the reactive sites were blocked with 1M 
ethanolamine and surface-immobilized EPCR was detected as follows: A) EPCR antigen 
was detected using rabbit polyclonal antibody against anti-EPCR and HRP conjugated 
goat anti-rabbit antibodies as primary and secondary antibody, respectively, B) the 
presence of binding epitope was detected using RCR-2, a monoclonal antibody against 
anti-EPCR and HRP conjugated goat anti-mouse antibodies as primary and secondary 
antibody, respectively, and C) functionality (i.e. PC binding) was detected using pure 
human Protein C and HRP-conjugated rabbit anti-Protein C antibodies.  Proteins were 
visualized with chemiluminiscent detection and quantified using Image software.
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Figure 3: Solution phase activation of Protein C in the presence and absence of 
EPCR 
Protein solutions of rEPCR, hTM, human thrombin, human PC, human APC were 
prepared in reaction buffer composed of 0.1 M NaCl, 0.003 M CaCl2, 0.0006 M MgCl2, 
0.02 M Tris-HCl, 0.1 mg/ mL BSA at pH 7.5.  25 µl of a 0.36 mg / ml rEPCR was 
incubated for 15 minutes with 25 µl of a 0.1 mg / ml hPC solution in a sterile 96 well cell 
culture plate. Following incubation, 25 µl of a 0.006 mg/ml TM solution and 25 µl 0.06 
µg / ml of human thrombin was added to the reaction mixture and Spectrozyme aPC was 
added to a final concentration of 0.0004 M.  The reaction was incubated at 37 oC with the 
absorbance at 405 nm-1 taken after 0, 5, 10, 15, 20, 30, 45, 60, 75, 90 and 105 minutes 
using a Beckman Coulter AD 340 UV / Vis microplate reader.  Samples were preformed 
in triplicate and for samples without either EPCR or TM, the solution was replaced 0.08 
mg / ml BSA solution.  The concentration of Protein C activated was calculated using an 
aPC in reaction buffer calibration curve on the same plate.
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Figure 4: PC activation on UltrabindTM membrane bearing EPCR and TM. 
The following protein samples were immobilized on UltrabindTM discs: 
TM:thrombomodulin alone; rEPCR: rEPCR alone; TM+rEPCR: co-immobilization of 
TM and EPCR, in a random fashion and (TM+RCR-2) + rEPCR:co-immobilization of 
TM and RCR-2, in a random fashion, followed by binding of rEPCR to RCR-2. Controls 
correspond to membranes with no TM or EPCR.  EPCR containing samples were spotted 
in a 7:1 EPCR:TM concentration similar to that seen in vivo. sample-1 (S1): control, no 
TM or rEPCR; sample-2 (S2): 10 ng/cm2 (140 femtomoles) of TM; sample-3 (S3): 50 
ng/cm2 (700 femtomoles) of TM; sample-4 (S4): 100 ng/cm2 (1400 femtomoles) of TM 
and sample-5 (S5): 200 ng/cm2 (2800 femtomoles) of TM.  Samples were incubated for 
30 minutes at 37 oC with 50 µl of a 5 units / ml thrombin solution.  Following incubation, 
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the thrombin solution was removed and a 50 µl of a 0.025 mg / ml hPC solution was 
added to each sample and incubated at 37 oC for 1.5 hours.  The reaction was stopped 
with the addition of 10 µl of anti-thrombin III to a final concentration of 6 units/ml and 
incubated for 15 minutes. Subsequently, the solution was pipetted from the solid samples 
to new 96 well plate.  To each solution sample, 40 µl of Spectrozyme aPC solution was 
added to a final concentration of 0.004 M and incubated at 37oC and absorbance at 
405nm-1 was measured as a function of time.  # and * denote statistically different from 
each other, p<0.05. 
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Chapter 4 
Development of a Biomimetic Vascular Surface by the Sequential 
 Co-immobilization of Thrombomodulin and EPCR on Polyurethane. 
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Abstract 
In the normal endothelium; thrombomodulin (TM) and endothelial protein C receptor 
(EPCR), are well-integrated to regulate the protein C (PC) anticoagulant pathway. The 
central goal of this study was to examine the influence of co-immobilizing rEPCR with 
TM either randomly or in a sequential fashion, on biomaterial surfaces, on the activation 
of PC.  As TM and EPCR work in concert, co-immobilization on the nanometer scale 
was desired to anchor the two proteins to enable the desired enzymatic activation when 
compared to random immobilizations. Polyurethane discs were surface modified to 
enable the ordered immobilization of proteins via a bidentate moiety, which includes 
reactive oxirane and carboxylic functional groups.  Random immobilizations were carried 
out via the oxirane arm of the bidenate moiety and all surfaces were prepared with the 
same defined surface concentrations of rEPCR and TM.  Random co-immobilizations of 
TM and rEPCR on modified PU surfaces yielded increased APC levels when compared 
to immobilization of TM, however the increases were statistically insignificant.  In 
contrast, sequential co-immobilizations of TM and rEPCR via the bidentate moiety on 
PU, which allows for immobilization at a molecular proximity, yield APC levels that 
were significantly (p<0.05) different from immobilizations of TM alone.  Further studies 
were conducted with protein immobilized surfaces and platelet poor plasma using a 
thromboelastograph to monitor the formation of fibrous clot formation in comparison to 
control unmodified surfaces and surfaces immobilized with common surface treatments 
such as albumin and heparin. 
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Introduction 
 
 Polymers such as polyesters, polyurethanes and polytetrafluoroethylene are often 
used for vascular implants because they are nontoxic with mechanical properties similar 
to those of vascular tissues.[1, 2]  However these polymer implants, like most other 
synthetic materials, can lead to thrombosis when subjected to blood.[3]  In the case of 
large diameter vascular implants these properties are harnessed to form a polymer fibrous 
composite graft, however for intermediate and small diameter grafts these thrombi lead to 
occlusions and failure of the implant.[2]  To overcome this phenomena, the surface of the 
polymer is chemically modified to passivate the surface, often by immobilizing 
molecules which alter the surface charge or hydrophobicity of the material.[4, 5]  Other 
surface modifications have immobilized anticoagulants such as hiruden[6] or 
biomolecules such as cholesterol[7].  Because the endothelial membrane of vascular 
tissue is naturally non-thrombogenic,[8] several studies have been conducted 
immobilizing membrane proteins and molecules known to inhibit fibrin formation or 
platelet adhesion including heparin, thrombomodulin, prostaglandin and nitric oxide.[9-
15]  These coating have shown promise because they are able to interact with the natural 
molecules used to control haemostasis in the blood such as anti-thrombin III and protein 
C.[16, 17] 
 While immobilizing a single protein of biomolecule on to the surface of a 
biomaterial allows it to mimic one specific pathway, the regulation of haemostasis 
involves many pathways working in concert.[8]  Because of this, studies have attempted 
to create surfaces which incorporate multiple aspects of the endothelial cell’s natural 
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regulatory molecules.  In two of these studies, a fibrin inhibitor such as heparin or 
thrombomodulin was co-immobilized with a platelet inhibitor such as prostaglandin or a 
nitric oxide producing molecule.[13, 18]  In another study, both thrombomodulin and 
heparin were immobilized onto surface with a phospholipid membrane.[10]  This 
membrane was meant to mimic the cell membrane inhibiting nonspecific protein binding 
and also enhance the thrombomodulin function by creating the proper alignment and 
present the proper environment for the transmembrane region of the protein. 
 Several of these studies have immobilized thrombomodulin because of its ability 
to activate Protein C when bound to thrombin.[19]  Protein C, once activated, inhibits the 
formation of Factor Va and Factor VIIIa, which stops the production of thrombin in the 
common pathway of the clotting cascade.[20]  However, naturally the function of 
thrombomodulin is enhanced by endothelial protein C receptor (EPCR), figure 1.[21, 22]  
EPCR is a transmembrane protein which has been shown to increase the transport of 
Protein C onto the material surface and when blocked has shown an 86% decrease in 
Protein C activation.[23]  Crystallographic studies of Protein C bound to EPCR show that 
when bound Protein C is in presented in an orientation that allows it to be activated by 
the thrombomodulin-thrombin complex suggesting that Protein C is activated while still 
bound to EPCR.[24]  This mechanism has been further confirmed by incubating Protein 
C with and without soluble EPCR prior to activation in solution phase, with the result of 
both having the same reaction rates.[25]  Should this mechanism hold true, it would 
require that the EPCR and thrombomodulin be localized together on the surface.  On the 
cell membrane, Protein C bound to EPCR has been determined through fluorescence 
energy transfer to be at a height of approximately 94 Å and thrombin bound to 
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thrombomodulin at approximately 64 Å above the cell membrane.[26]  If these protein 
complexes were approximated as a sphere with the height as the diameter where the 
reaction sites are able move along the surface of the sphere this would require that EPCR 
and thrombomodulin be immobilized on a surface by a separation of less than 80 Å, or 8 
nm. 
 Different techniques have been developed to pattern immobilize biological 
molecules onto the surface of materials.  Techniques such as photomask lithography, 
nanografting and nanoimprinting have all be used to create patterns onto polymer 
supports, however these techniques all have limitations.  Photomask lithography, a 
technique where a monolayer or polymer is coated either physically or chemically with 
photo-active polymer and a light source through a patterned cover immobilizes the target 
protein in the pattern on the surface.[27-29]  This method is limited by low resolution on 
the mask and has been limited to micron and submicron patterns.  Nanografting is a 
technique where proteins are loaded onto an AFM probe and then touched to the surface 
in the desired pattern.[30]  While this method does offer the resolution necessary, it can 
not be easily scaled to a manufacturing level.  Nanoimprinting is a technique where a 
stamp is created through one of the other lithography techniques and is printed onto the 
surface through direct contact.[31]  The limitations of this technique are life of the stamp, 
the resolution of the protein pattern during the stamping process and the alignment 
needed for the stamp or multiple stamps in the case of co-immobilization.  
 This research proposes the co-immobilization of thrombomodulin and EPCR  
onto a polyurethane support.  In this method, figure 2, the two proteins will be 
immobilized using a bidentate functional group synthesized on the surface of a post 
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fabricated polyurethane sample across the solid / liquid interface.  We hypothesize that by 
immobilizing thrombomodulin and EPCR onto the surface via the bidentate functional 
group, that the distance between the two proteins can be controlled such that the activity 
of thrombomodulin on the surface is enhanced as measured by Protein C activation in 
comparison to blank surface, surfaces modified with thrombomodulin alone and samples 
with a random co-immobilization of the two proteins.  We further hypothesize that the 
co-immobilization of thrombomodulin and EPCR will delay the formation of fibrous 
clots.
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Methods 
 
 Chronoflex AR medical grade polyurethane was generously provided as a gift 
from Cardiotech Inc. (Cambridge, MA).   
 
2.1 Preparation of Surface Bridge 
 The chemical representation of the proposed surface modification scheme is 
shown in figure 2.  Reaction 1 will enable the addition of the first reactive oxirane moiety 
to the secondary nitrogen incorporated in the carbamate subunit of the PU backbone.  The 
addition of the reactive carboxylic acid branch of the bidentate bridge is achieved in 
reaction 2.  Reaction 3 enables the addition of a reactive oxirane functional group to 
complete the bidenate bridge.  Subsequent paragraphs will provide the experiment details 
of the surface modification. 
 
2.1.1 Reaction 1  
Solution cast polyurethane films were cut into 0.5 cm diameter samples with an average 
weight of 30 mg using a standard biopsy punch.  Under an inert atmosphere, 
approximately 1 gram of polyurethane was added to 75 mL tetrahydrofuran (THF, HPLC 
Grade 99.9%, Sigma Aldrich, St. Louis, MO) mixed with 75 mL hexanes (ACS Grade, 
Sigma Aldrich, St. Louis, MO) and the temperature of the mixture reduced to -5 oC using 
an isopropyl alcohol ice bath.  0.5 mL epibromohydrin and 0.5 mL of a 2.0 M lithium 
diisopropyl amine (LDA, Sigma Aldrich, St. Louis, MO) in THF were added to the 
mixture and the reaction was allowed to proceed for 2.5 hours with stirring.  Upon 
completion, the LDA, THF solution was removed from the PU samples and neutralized 
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with a 3% (V/V) acetic acid solution.  The PU samples were washed with 150 mL 
deionized water for 30 minutes and repeated 3 times to remove excess THF / Hexane 
solution.  Residual solvent was removed under reduced pressure, P < 0.3 Torr for at least 
6 hours. 
 
2.1.2 Reaction 2  
PU samples from reaction 1 were added to a 0.02 M 5-amino valeric acid (Sigma 
Aldrich, St. Louis, MO) in water.  The samples were allowed to react at room 
temperature for 24 hours with stirring.  Samples were washed with 150 mL deionized 
water for 30 minutes and repeated 3 times.  All absorbed water was removed by 
evaporation under reduced pressure, P < 0.3 Torr for at least 6 hours. 
 
2.1.3 Reaction 3 
Under an inert atmosphere, PU samples from reaction 2 were added to a 150 ml mixture 
THF  and hexanes (50/50 by volume) and the temperature of the mixture reduced to -5 oC 
in an isopropyl alcohol ice bath.  0.5 mL epibromohydrin and 0.5 mL of a 2.0 M lithium 
diisopropyl amine (LDA, Sigma Aldrich, St. Louis, MO) in THF were added to the 
mixture and the reaction was allowed to proceed for 2.5 hours with stirring.  Upon 
completion, the LDA, THF solution was removed from the PU samples and neutralized 
with a 3% (V/V) acetic acid solution.  The PU samples were washed with 150 mL 
deionized water for 30 minutes and repeated 3 times to remove excess THF / Hexane 
solution.  Residual solvent was removed under reduced pressure, P < 0.3 Torr for at least 
6 hours.  Samples were at room temperature until use. 
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2.2 Protein Immobilization 
 Protein solutions of recombinant EPCR-his, human thrombomodulin (TM, 
American Diagnostica Inc., Stamford, CT) and rabbit lung thrombomodulin (rTM, 
American Diagnostica Inc, Stamford, CT) were prepared in PBS buffer (pH 7.2). 
 
2.2.1 Protein 1 via Carboxylic acid 
A 0.1 g / mL solution of 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride 
(EDC, Thermo Fisher Scientific, Rockford, IL) was prepared in a 0.1 M 2-(N-
Morpholino)ethanesulfonic acid (MES, Sigma Aldrich, St. Louis, MO) solution pH 4.5.  
500 μL of the EDC in MES solution was added to each sample and was allowed to react 
at room temperature with shaking.  After 15 minutes, 500 μL of a 20 mg / mL N-
hydroxysulfosuccinimide (Sulfo-NHS, Thermo Fisher Scientific, Rockford, IL) in MES 
buffer and added to each sample’s solution.  After 30 minutes at room temperature, the 
solution was removed from each sample and 100 μL of protein 1 in solutions prepared in 
phosphate buffered saline (PBS, pH7.2) was added to each PU samples from reaction 3 
for 6 hours at room temperature.  Upon completion, the PU samples were washed with 2 
mL of PBS per sample 2 x 30 minutes. 
 
2.2.2 Protein 2 via Oxirane 
Following the immobilization of protein 1, 100 μL of protein 2 prepared in PBS was 
reacted for 24 hours at 4oC.  The samples were washed 2 x 30 min PBS, 2 x 30 minutes 
PBS +.05% Tween 20, 3 x 30 min PBS. 
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Following final protein attachment the samples were stored in reaction buffer composed 
of 0.1 M NaCl (Sigma Aldrich, St. Louis, MO), 0.003 M CaCl2 (Sigma Aldrich, St. 
Louis, MO), 0.0006 M MgCl2 (Sigma Aldrich, St. Louis, MO), 0.02 M Tris-HCl (Fisher 
Scientific, Pittsburgh, PA), 0.1 mg/ mL Bovine Serum Albumin (BSA, Sigma Aldrich, 
St. Louis, MO) and the pH adjusted to 7.5.  at 4oC. 
 
2.3 Solid Phase Protein C Activation Assays 
2.3.1 Solid Phase Protein C Activation Assays Low Thrombin Concentration 
 Samples prepared previously were washed in 50 µl fresh reaction buffer prior to 
reaction.  Samples were incubated for 30 minutes at 37 oC with 50 µl of a 5 units / ml Thr 
solution with mixing.  Following incubation, the thrombin solution was removed but the 
samples not washed.  50 µl of a 0.025 mg / ml hPC solution was added to each sample 
and reacted at 37 oC with mixing for 1.5 hours.  The reaction was ended by the addition 
of 10 µl of anti-thrombin III (American Diagnostica Inc., Stamford, CT) to a final 
concentration of 6 units / ml.  Following 15 minutes of reaction of anti-thrombin with 
thrombin from the reaction, the solution was pipetted from the solid samples to new 96 
well plate.  To each solution sample, 40 µl of Spectrozyme aPC solution was added to a 
final concentration of 0.004 M.    Solution samples were incubated at 37oC analyzed 405 
nm-1. 
 
2.3.2 Solid Phase Protein C Activation Assays High Thrombin Concentration 
 Samples prepared previously were washed in 50 µl fresh reaction buffer prior to 
reaction.  Samples were incubated for 30 minutes at 37 oC with 50 µl of a 5 units / ml Thr 
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solution with mixing.  Following incubation, 50 µl of a 0.025 mg / ml hPC solution was 
added to each sample and reacted at 37 oC with mixing for 1.5 hours.  To end the 
reaction, the solution was pipetted from the solid samples to new 96 well plate.  To each 
solution sample, 25 µl of Spectrozyme aPC solution was added to a final concentration of 
0.004 M.    Solution samples were incubated at 37oC and analyzed at 405 nm. 
 
2.4 Thromboelastograph 
Platelet poor plasma (PPP) was prepared from fresh, drawn less than 36 hours prior to 
usage and never frozen, whole citrated blood (Research Blood Components LLC, 
Brighton, MA) prior to each experiment by centrifuging whole citrated blood at a force of 
2300 x g for 15 minutes at room temperature.  Samples were inserted into disposable 
chambers which had been bored out to a diameter of 0.406 inches and 425 μL PPP was 
added.  Clotting was initiated with the addition of a 200 mM CaCl2 60 mM MgCl2 
solution to a final calcium concentration of 6.0 mM.  Samples were analyzed using a 
Thromboelastograph Analyzer 5000 (Haemoscope, Niles, IL) for speed of onset of the 
clot, initial formation rate of the clot and maximum strength of the formed clot. 
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Results 
3.1 Polyurethane Sample Prepration 
 The characterization of the bidentate functional group modification to 
polyurethane samples has been discussed earlier as well as the ability to bind proteins to a 
specific end of the functional group. 
 Solid samples were prepared from TM solutions to produce a surface density of 
TM of 50 ng/cm2 based upon 50 % completion and considering the samples to be 2 
dimensional (no width) and two faces.  This value is approximately 4.5 times the surface 
density found on native vascular endothelial surfaces.[32]  The EPCR was added at a 7:1 
molar ratio to TM based upon the ratio of the two proteins seen in native tissue.[32]  This 
ratio was kept even in sequential reactions despite the bidentate functional group having a 
only two reaction sites per functional group.  All samples we blocked with ethanol amine 
and stored under buffer containing BSA to ensure the opening of all oxirane attachment 
sites. 
 Because the different chemistries have the potential to bind to different sites on 
the protein, it was necessary to compare the activity of TM when bound to either the 
oxirane or acid end of the functional group.  As can be seen in figure 3, no significant 
difference can be seen in the activity of TM.  With no significant difference seen in the 
activity, all samples were prepared with proteins added through the oxirane functional 
group except in the case of samples with ordered co-immobilization which were prepared 
with TM immobilized through the acid group and EPCR added through the oxirane. 
 
3.2 Protein C Activation Assay 
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 The protein C activation assay was conducted in two different manners, in the 
presence of a low concentration of thrombin and in the presence of a high concentration 
of thrombin.  In each of these experiments the initial concentration of thrombin added 
was the same, however in the low thrombin concentration experiments the thrombin 
solution was removed after incubation.  In low thrombin experiments sample modified 
with TM and EPCR both through the oxirane were not able to activate Protein C at a rate 
greater than that of TM alone, similar to what was seen on ultrabind surfaces in the 
previous chapter.  However, samples with the sequential immobilization showed a 
increase in the activation of Protein C over both the TM alone (p = 0.05) and the random 
co-immobilization to TM and EPCR ( p < 0.001).  In high thrombin experiments, both 
the sequentially ordered (p < 0.001) and the randomly immobilized (p = 0.02) showed a 
significant increase in the ability of the surface to activate Protein C, however in this 
experiment as well the sequentially ordered samples were able to activate significantly 
more Protein C than randomly immobilized samples (p < 0.05). 
  
 
3.3 Thromboelastograph 
 Thromboelastography (TEG) is a method of testing the efficiency of coagulation 
in the blood and measures the changes in elasticity at all stages of the developing and 
resolving clot.  To evaluate the effect of the protein immobilized PU surfaces on the 
efficacy of coagulation, samples were studied by thromboelastography using platelet poor 
plasma (PPP).  The time taken to initial fibrin formation and clot onset were evaluated for 
modified PU films immobilized with rabbit TM, rabbit TM and EPCR in a random 
 142
bonding and rabbit TM and EPCR in a sequentially ordered immobilization.  These 
samples were compared to modified films and films immobilized with BSA or Heparin, 
two standard non-thrombogenic coatings.  The data was plotted in figure 6 and the data 
for initial fibrin formation (SP) and time to clot initiation (R) plotted in figures 7 and 8 
respectively with the values normalized to control bare surfaces show in figure 9.  
Because of restraints on both the polymer material and the amount of recombinant 
protein available and because the samples could not be reused following the exposure of 
PPP prepared from human blood, this experiment was run only twice with samples in 
triplicate.  Because of the small number of data points and the experiment being run only 
twice, it was difficult to establish high confidence limits for this experiment.  As a result 
data was compared as established for p< 0.03, suggested p< 0.10 and possible for p< 
0.20.  These relationships for TM, TM / EPCR random and TM / EPCR ordered 
compared the controls and each other are described in figure 10.
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Discussion 
 There is a significant need to design vascular grafts which contain similar 
mechanical properties of natural vascular tissue and are non-thrombogenic when 
contacted with blood.  While different biomedical polymers have been used to 
approximate the mechanical properties of native arteries, these polymers have been 
shown to be thrombogenic, requiring surface modifications to pacify the surface to blood 
contact.  As a result of this need, several groups have studied the native endothelium of 
vascular tissue and attempted to mimic its methods of controlling haemostasis.  In these 
studies, endothelial membrane bound molecules such as heparin or thrombomodulin 
(TM) have been immobilized onto biomaterials surfaces in the hope of controlling 
thrombin formation on their surface.[33, 34]  However the regulation of haemostasis is 
complex several surface groups, many of which have cofactors.  On large arteries, TM is 
co-localized with endothelial protein C receptor (EPCR) which is thought to increase the 
transport of Protein C onto the endothelial surface.[35]  
 To take advantage of the increased transport of Protein C by EPCR, it was 
necessary to immobilize EPCR and TM to the bidentate functional group to maintain a 
physical distance which could be bridged and allow the reaction to proceed.  Our initial 
tests were to determine if the activity of TM changed when bound to each of the reactive 
sites of the bidentate functional group, figure 3.  With no significant difference, the 
ability of TM to activate Protein C was studied on surfaces with TM alone, TM and 
EPCR in a random orientation and TM and EPCR immobilized sequentially to one side 
of the functional group.  The static tests were conducted in two separate manners based 
upon the total thrombin concentration.  Previous studies have incubated their samples 
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with thrombin to allow the binding of thrombin to TM on the surface and then removed 
the thrombin solution prior to Protein C activation.  This could be to avoid the possibility 
of Protein C activation by unbound thrombin which is a very slow reaction.  However the 
binding of thrombin to TM is a reversible process and with the removal of the thrombin 
solution there is no boundary concentration of free thrombin.  Because of the lack of a 
boundary layer concentration close to the material surface, and thrombin that is released 
during the reaction will not be reabsorbed onto the surface.  This phenomena does not 
follow the process in vivo where thrombin production is on the injured cell or biomaterial 
surface.  To better model this event, the excess thrombin solution was included in the 
reaction mixture during Protein C activation.  As can be seen in figure 4, a significant 
increase was seen in Protein C activation in both low and high thrombin experiments for 
samples with ordered immobilization over samples immobilized with TM alone and TM 
and EPCR in a random orientation.  While the increase was significant, it was not the 7x 
increase that is seen on arteries.[35]  This could be do to several factors, first the 
alignment of EPCR and TM was not controlled, so while the distance was controlled the 
proteins could be could be bound to the surface in a manner that blocks the reactive site.  
Another possible reason for the small increase is that despite the 7:1 immobilization of 
EPCR to TM on the surface which is based upon the concentration of the two proteins on 
large arteries[32], the bidentate functional group is only 1:1 meaning that largest 
concentration of EPCR is most likely not immobilized at a distance which can directly 
interact with TM. 
 Both of these concerns should have been addressed by the immobilization of 
RCR2, an antibody against EPCR, with TM in an ordered configuration.  RCR2 binds 
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EPCR on the cytosolic portion of the protein near the transmembrane region meaning that 
bound EPCR should be in the proper orientation.  RCR2 also has the ability to bind 
EPCR to both Fab regions of the antibody meaning it could bind 2 molecules of EPCR 
for every RCR2 molecule.  However samples with RCR2 showed a significant decrease 
when compared to samples with TM and EPCR alone, figure 5.  This decrease in activity 
was believed to be the result of steric interference from too high a density of proteins for 
the thrombin and Protein C to bind and migrate to an alignment to react. 
 Polyurethane samples with immobilized proteins were analyzed for their affect on 
fibrin clot formation by thromboelastograph (TEG) using platelet poor plasma (PPP).  
PPP was used to eliminate the effect of platelets on thrombus formation to prove whether 
co-immobilized EPCR with TM would have an effect on fibrin formation.  Two 
parameters were focused on, SP which is the time when the TEG first detects thrombin 
formation and R which is the reaction time measured at the time of first significant clot 
formation.  In both of these measurements, times were significantly increased for samples 
with EPCR co-immobilized with TM over bare polymer or polymer immobilized with 
bovine serum albumin, a method of pacification, figures 7-10.  It is difficult to compare 
EPCR /TM samples to TM alone as this test was only able to be run twice with samples 
in triplicate due to restrictions on the quantity of both polymer and recombinant proteins 
and TM samples while had agreement to their test group, created a large standard 
deviation upon the two sets being unified.  While no significant difference could be 
detected between EPCR / TM in a random immobilization and samples with either TM 
alone or with the same number of pharmaceutical units of immobilized heparin.  A 
possible difference could be seen when comparing TM / EPCR in an ordered 
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immobilization to samples of TM alone and samples with heparin, however more testing 
would be necessary to confirm these results. 
 Also of interest is the ratio of increase over control samples for TEG samples as 
compared to the Protein C activation assays.  For the SP measurement the ratio of 
Ordered compared to TM alone was 5.7:1 and the for the R values 2:1 where as for the 
activation assays ordered samples averaged 1.5:1.  While these values do measure 
different processes, these processes are related as they both are products of the regulation 
of thrombin.  Since the thrombin concentrations on the surfaces of the samples are the 
same, the change must be related to an increase in the EPCR transport.
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Conclusions 
 With the growing development of biomimetic surfaces, the co-immobilization of 
proteins and their cofactors onto surfaces need to be studied to better interact with the 
body and its physiology.  To date, these methods have been limited to random 
immobilizations which do not ensure that the immobilized molecules are able to react 
with each other as they would in the body. 
 We have demonstrated a method to immobilize thrombomodulin and endothelial 
Protein C receptor using a bidentate functional group extended from the surface of 
polyurethane in an effort to create a less thrombogenic surface.  Samples immobilized 
with this protein system have demonstrated a greater ability to activate Protein C in both 
high and low thrombin systems.  Finally, we have shown that the ordered system is able 
to delay fibrin formation and fibrous clot formation over unmodified polymer, polymer 
with an immobilized BSA coating and samples immobilized with thrombomodulin alone.  
We have also show that samples with this system inhibits clot formation as well as and 
possibly better than a polyurethane with a heparin coating.
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Figure 1 Representation of Protein C Activation on the Vascular Endothelium 
Representation of the mechanism of activation of the anticoagulant Protein C by a) 
thrombomodulin (TM) alone and b) thrombomodulin and endothelial protein C receptor 
(EPCR) 
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Figure 2 Chemical Representation of Thrombomodulin and EPCR to Polyurethane 
through the bidentate functional group.   
 
Covalent immobilization of the proteins TM and EPCR via the bidentate functional group 
for ordered immobilization.  This representation demonstrates TM being immobilized 
through the carboxylic acid group and EPCR through the oxirane as was the case in the 
data reported in this chapter, however immobilization of EPCR through the acid and TM 
through the oxirane yielded no statistical difference (data not shown).
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Figure 3: Functional activity of TM immobilized on PU via reaction 2 and 
reaction 3. 
 
In separate experiments, a desired concentration of 100 ng/cm2 (1400 femtomoles) of 
TM was immobilized via –COOH group (reaction 2) and via the oxirane group (reaction 
3).  Functional activity of immobilized TM (i.e PC activation in the presence of 
thrombin) was assayed by incubating samples with thrombin for 30 minutes and 
procedure as detailed in legend to figure 4 was followed.  
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Figure 4 Protein C Activation 
 
Protein C activation in high and low thrombin concentration experiments by polyurethane 
samples immobilized with thrombomodulin (TM), thrombomodulin and EPCR randomly 
immobilized and thrombomodulin and EPCR sequentially immobilized.  All values 
normalized to concentration of activated Protein C (aPC) produced by polyurethane 
samples immobilized with thrombomodulin alone. * represents statistically higher than 
control (p<0.05) 
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Figure 5: PC activation on PU surfaces bearing EPCR and TM. 
The following protein samples were immobilized on PU discs: TM:thrombomodulin 
alone; TM+rEPCR: co-immobilization of TM and EPCR, in a random fashion; 
TM/rEPCR: sequential immobilization of TM and EPCR, in a directed fashion; 
(TM+RCR-2)+rEPCR: co-immobilization of TM and RCR-2, in a random fashion, 
followed by binding of rEPCR to RCR-2 and (TM/RCR-2)+rEPCR: sequential 
immobilization of TM and RCR-2, in a directed fashion, followed by binding of rEPCR 
to RCR-2. Controls correspond to membranes with no TM or EPCR.  EPCR containing 
samples were spotted in a 7:1 EPCR:TM concentration similar to that seen in vivo. A 2:1 
rEPCR:RCR-2 stoichiometry and 20% antigen binding efficiency was assumed in 
calculating the amount of RCR-2 immobilized (750 ng/cm2).  Functional activity of 
surfaces bearing TM and EPCR (i.e PC activation in the presence of thrombin) were 
assayed using the low thrombin method.  # and * denote statistically different from each 
other, p<0.05. 
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Figure 6: Thromboelastograph Representative Data 
 
Modified PU samples immobilized with BSA, TM, TM/EPCR ordered immobilization, 
TM/EPCR random immobilization and heparin were inserted into disposable chambers 
which had been bored out to a diameter of 0.406 inches, and 425 μL of PPP was added.  
Clotting was initiated with the addition of a 200 mM CaCl2 and 60 mM MgCl2 solution 
to a final calcium concentration of 6.0 mM.  Samples were analyzed using a 
Thromboelastograph Analyzer 5000 for time to initial fibrin formation (SP) and time to 
initial clot formation (R). 
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Figure 7: Initial Fibrin Formation  
 
Modified PU samples immobilized with BSA, TM, TM/EPCR ordered immobilization, 
TM/EPCR random immobilization and heparin were inserted into disposable chambers 
which had been bored out to a diameter of 0.406 inches, and 425 μL of PPP was added.  
Clotting was initiated with the addition of a 200 mM CaCl2 and 60 mM MgCl2 solution 
to a final calcium concentration of 6.0 mM.  Data reported for time to initial fibrin 
formation (SP).
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Figure 8 Time to Initial Clot Formation 
 
Modified PU samples immobilized with BSA, TM, TM/EPCR ordered immobilization, 
TM/EPCR random immobilization and heparin were inserted into disposable chambers 
which had been bored out to a diameter of 0.406 inches, and 425 μL of PPP was added.  
Clotting was initiated with the addition of a 200 mM CaCl2 and 60 mM MgCl2 solution 
to a final calcium concentration of 6.0 mM.  Data reported for time to initial clot 
formation (R) which correspondes to the endpoint of an activated partial thromboplastin 
time (APTT). 
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SP 
(sec) Std Dev R (sec) Std Dev 
Control 1.00 0.31 1.00 0.06 
BSA 1.11 0.07 1.08 0.02 
TM 1.07 0.43 1.13 0.23 
TM/EPCR 
Ordered 1.40 0.15 1.26 0.18 
TM/EPCR 
Random 1.32 0.13 1.20 0.06 
Heparin 1.32 0.15 1.14 0.13 
          
Control 
(Actual) 285.00   346.67   
 
Figure 9: Values for SP and R  
 
Comparison of values for time to initial fibrin formation (SP) and initial clot formation 
(R) measured using PPP in contact with PU with different surface immobilizations.  Two 
independent experiments with samples in triplicate were analyzed.  Clotting was initiated 
with the addition of a 200 mM CaCl2 and 60 mM MgCl2 solution to a final calcium 
concentration of 6.0 mM.
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  Controls Samples 
  No Protein BSA Heparin TM 
TM / 
EPCR 
random 
TM / EPCR 
ordered 
SP N/D N/D Possible worse - Possible  Suggested TM 
R Possible N/D N/D - N/D Possible 
SP Established Established N/D Possible - Possible TM / EPCR 
random 
R Established Established N/D N/D - N/D 
SP Established Established Possible Suggested Possible - TM / EPCR 
ordered 
R Established Established Possible Possible N/D - 
 
Figure 10: Comparison of clotting parameters (SP and R). 
 
 
Due to limited number of samples for thromboelastography experiments, 2 runs with 
samples in triplicate, the following constraints were made for analyzing potential 
differences between sample types.  P<0.03 denotes that statistical difference between 
sample and control was established. P<0.1 denotes a statistical difference between sample 
and control was possible. P<0.2 denotes a statistical difference between sample and 
control was suggested. N/D not determined.  
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Future Experiments Suggested for the Thrombomodulin-Endothelial Cell Protein C 
Receptor Functionalized Surface and a Sequentially Immobilized Surface 
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Future Work 
 
 This dissertation has presented an approach for the development of a novel 
biomimetic vascular surface, however there are several areas which must be studied 
before this could be developed into a potential vascular graft.  This chapter will describe 
possible future directions for the both the EPCR / TM endothelial cell mimicking surface 
as well as the other possible projects for the sequential immobilization chemisty. 
 
Experiment Set 1: Determine the effects of flow on the production by the functionalized 
surface of the anticoagulant Activated Protein C.  I predict that more Protein C will be 
activated in tubing functionalized with the EPCR / TM complex than in native tubing or 
tubing functionalized with TM or EPCR alone.  I also predict based upon the conclusions 
formed in chapter 4, that the patterned immobilization will show more activity than a 
random co-immobilization, especially in low concentrations of thrombin. 
 In these studies commercially available polyurethane (PU) tubing constructed 
from Chronoflex AR will be purchased from Cardiotech Inc.  Following the procedures 
developed in chapter 1, the luminal side will be functionalized and immobilized with both 
TM and EPCR, TM alone and BSA.  PC reaction buffer described in chapter 3 and 4 with 
spectrozyme added and a standard UV chromatography sensor analyzing at 405 nm will 
be used to determine the concentration of PC activated.  Activation will be analyzed on 
surfaces which are pre-incubated for 1 min with thrombin solution (low thrombin 
experiment chapter 3 and 4) and with thrombin incorporated (high thrombin experiment) 
as well as at various flow rates in the arterial and venous flow regimes.  Two control 
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surfaces will be incorporated into the experiment, unmodified PU and BSA immobilized 
PU.  The BSA immobilized will serve two separate purposes as a control, first BSA 
coated surfaces are in general considered to non-thrombogenic.  The second purpose of 
the BSA immobilized sample is that it will act as a control of protein adsorption onto the 
bare PU surface creating improper measurement. 
 
Experiment Set 2: Determine the immunogenicity of recombinant EPCR produced in 
Pichia pastoris.  While recombinant proteins produced in Pichia pastoris have 
glycosylation patterns at the same positions as mammalian proteins and shorter than 
bacteria and other yeast, the glycosylation pattern is still recognized by the human 
immune system as derived from fungi and as such can initiate an immune response.  It is 
necessary to determine how the immune system will react to recombinant EPCR as an 
adverse immune response can lead severely decrease life expectancy of the proteins on 
the surface or rejection of the implant.  I predict that recombinant EPCR grown in Pichia 
will lead to the activation of the immune system.  
 In this experiment, recombinant EPCR in both glycosylated and deglycosylated 
form will be incubated in separate samples over mouse macrophages cultured on a tissue 
culture plate.  Following incubation the macrophages will be examined for activation.  In 
another experiment, solution suspended macrophages will be incubated with surface 
bound EPCR.  Should both the glycosylated and deglycosylated forms of recombinant 
EPCR activate mouse macrophaege, clones for recombinant EPCR produced in Chinese 
Hamster Ovary (CHO) or humanized Pichia cells.  The products of these cells will then 
be tested for both immune response and activity. 
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Experiment Set 3: Determine the long term stability of the protein complex formed and 
immobilized on functionalized surface.  The longterm stability of any surface coating 
must be determined to understand the life expectancy on an implantable device.  Previous 
studies have shown that TM immobilized surface show a loss of activity which stabilizes 
after 3 months.[1]  Studies of PU immobilized samples showed that sequentially 
immobilized samples degraded at a slower rate than did TM alone immobilized samples 
though not enough samples or readings were included to create a statistically relevant 
experiment and as such this data was not included within this dissertation.  I predict that 
as was seen in previous samples that sequentially immobilized samples will degrade at a 
slower rate and that the ration of aPC produced will increase in comparison to samples 
with TM immobilized alone. 
 This experiment will include PU immobilized with TM alone, TM and EPCR and 
TM and a completely deglycosylated EPCR.  Samples will be designed for both static 
and flow experiments and analyzed at two week intervals to determine PC activation.  
When not being used for experiments, samples will be kept at 37oC and stored in Hank’s 
Buffered Saline solution with 1% BSA.  Samples will be incubated at 37oC to simulate 
implanted conditions.  A second experiment should include incubation with platelet poor 
plasma (PPP) to test for stability against proteolytic damage to the immobilized 
recombinant proteins.  In this experiment citrated blood should be used to prevent fibrin 
formation on the surface which could create an artificial fouling of the surface.  Prior to 
each experiment samples should be washed for 24 hours with recirculating sterile PBS 
with 1% BSA to wash samples followed by experimentation to determine PC activation. 
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Experiment Set 4: Characterize the blood compatibility of the functionalized surface 
including platelet adsorption and thrombus formation in situ.  We predict that platelet 
adsorption will be similar on all functionalized surfaces and that the EPCR / TM 
functionalized surface will have a delayed clotting time, similar to that seen in our 
preliminary results.   In addition it is believe that any thrombi formed upon reaction with 
EPCR/TM immobilized samples will have a less stable clot formed when compared to 
control samples, those immobilized with TM alone or BSA. 
 Experiments will be conducted first with washed platelets, then with platelet rich 
plasma (PRP).  In both static and flowing experiments, samples will be tested for platelet 
adhesion and activation.  In addition this experiment will thrombin production levels 
following incubation with platelets.  In this method, the ability surface activated PC to 
arrest thrombin formation will be studied with platelets which can once activated form a 
surface for thrombin activation.[2, 3]  In other studies, thromboelastograph (TEG) studies 
will be conducted on protein immobilized surface with PRP and with whole blood.  
Studies with whole blood are important as in coagulation in vivo, it is often found that 
red blood cells become entrapped in the fibrous clot creating a more stable clot.  It is 
believed that clots on TM/EPCR surface will be less stable because the greater quantities 
of PC will be activated limiting thrombin formation formation and fibrin formation and 
crosslinking.[4] 
 
Experiment Set 5: Evaluate the function of the protein immobilized surfaces in vivo.  
Because of the nature of drawn blood to require the addition of an anticoagulant, it is 
necessary for flow experiments to be conducted in vivo.  I predict that the activation of 
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Protein C will occur in vivo similarly to those experiments in situ which will delay or 
prevent thrombus formation. 
 In situ experiments can only give so much information on the actual enzymatic 
responses of blood and the process of haemostasis.  Protein functionalized tubing will be 
implanted into excised portions of the femoral artery and large diameter vein of a rat 
model.  Samples will be impanted for different intervals between 1 hour and 24 hours.  
Following experiments rats will be sacrificed and the implants excised for analysis.  
Following sufficient washing samples will be analyzed to activated platelets, fibirous clot 
formation and occlusion. 
 
Experiment Set 6: Utilize the sequentially immobilized surface to create a cell seeded 
and directed vascular surface.  The seeding of cells onto a surface requires a binding 
point on the material surface.  This binding point can include a physical depression in the 
material surface, a surface bound peptide or absorbed proteins cover the surface.  While 
cells will bind to the surface, most cells also require a chemical, mechanical or membrane 
receptor induced stimulus to differentiate to the correct phenotype.   In this experiment 
the surface will be functionalized with the bidentate functional group.  To one side of the 
functional group, peptides which have demonstrated an ability to bind cells such as the 
sequence RGD or YIGSR subunits will be attached.  To the other terminal of the 
functional group we will attach growth factors which act through surface receptor 
mediated stimulations. 
 Surface will be created with either RGD peptide, fibroblast growth factor, both or 
bsa immobilized through the bidentate functional group.  Surfaces will be seed with L929 
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mouse fibroblasts through both static or flow seeding.  Surfaces will then be cultured for 
7days and then analyzed for proliferation through the MTT assay, trypsinized to count the 
number of adhered cells and then isolated for RNA.  Following isolation of RNA, cells 
will be analyzed by real time quantitative PCR to determine whether specific phenotype 
markers and ECM producing genes have been up-regulated in relationship to house 
keeping genes.  Secondary experiments will be conducted with RGD peptides and 
vascular endothelial growth factor (VEGF) can increase the seeding, differentiation and 
proliferation of endothelial progenitor cells.  Finally surfaces will be immobilized with 
YIGSR and VEGF and binding attempted with mesenchymal stem cells to determine if 
the surface can aid in proper differentiation of the stem cells.  These surface will be 
analyzed for gene transcription as described above but also for proper blood flow over the 
material surface.  
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